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ABSTRACT
PROBING THE ANTI-CANCER MECHANISM OF SELENITE: A
METABOLIC APPROACH
Alex Belshoff
June 19, 2013

The following dissertation was aimed at characterizing the metabolic disruptions
that occur with selenite treatment in human lung cancer. Specifically, the
pathways of glycolysis, TCA cycle, nucleotide metabolism, pentose phosphate
pathway, hexosamine biosynthetic pathway, and glutaminolysis were examined
thoroughly. A stable isotope-resolved metabolomic (SIRM) approach utilizing the
tracers 13C6-glucose and 13C5,15N2-Gln was employed in order to trace the flow of
atoms through the metabolic network. By utilizing this approach and a
combination of NMR and MS analyses, the metabolic pathways perturbed by
selenite were reconstructed based on measured isotopologues and isotopomers
and known biochemical reaction mechanisms. These methods were employed in
both cell-based and individualized ex vivo lung cancer tissue models developed
from an ongoing NSCLC patient study. In the A549 cell model, glycolysis was
upregulated by selenite treatment with a corresponding decrease in flux through
the TCA cycle and increase in flux through lactate dehydrogenase. These effects
were propagated through nucleotide synthesis by inhibiting the rate of carbon
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and nitrogen incorporation into nucleobases. Furthermore, UDP-GlcNAc
synthesis was diminished by selenite treatment, particularly in terms of its uracil
subunitand acetyl group incorporation. These findings were specific to cancer
cells and not observed in non-transformed NHBE cells and were recapitulated in
the patient data. The KGA splice variant, GAC, was greatly reduced by selenite
treatment, which was consistent with the metabolic data and reduction in
glutaminase activity. Again, this effect was not observed in NHBE cells.
Proliferation of A549 cells was at least partially restored upon supplementation of
selenite-treated cells with Glu, the product of the glutaminase reaction, validating
the importance of glutaminase in selenite-mediated cytotoxicity, including the
synthesis of glutathione for detoxifying excess ROS. Finally, findings from the
tissue slice data suggested that selenite induced a decrease in the synthesis of
glycogen. The brain form of glycogen phosphorylase (PYGB) was suppressed
using shRNA in order to characterize the metabolic consequences. Glycogen
was identified as an important source of fuel for A549 cells, since suppression of
PYGB resulted in reduced growth and colony formation accompanied by
decreased nucleobase synthesis, TCA cycle activity, and amino acid synthesis.
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CHAPTER 1
1.1 Introduction
It is estimated that 1.66 million people in the US will be diagnosed with some
form of cancer and that 580,000 people will die from cancer in 2013 [1]. The
current risk for a cancer diagnosis during one’s lifetime is approximately 40%,
which is a reduction of only 0.9% and 0.3% for men and women, respectively,
from 1999-2010 [1]. Furthermore, the reduction in cancer deaths for this time
period decreased by only 1.5% [1]. In the US, death from cancer is currently the
second highest cause of death behind only cardiovascular disease, but is above
chronic obstructive pulmonary disease (COPD), stroke, and accidents [2]. The
problem is particularly severe for lung cancer, which causes the greatest number
of cancer deaths worldwide with an estimated 228,000 diagnoses and 159,000
deaths in the US alone for 2013 [3]. Currently lung cancer is the 3rd most
common form of cancer behind breast and prostate, despite decreases in its
prevalence and death rate of 2.6% and 2.2%, respectively, from 2005-2010 [1].
However, these reductions are mostly due to a decrease in the prevalence of
smoking with only small improvements in lung cancer diagnosis or management.
Obviously, smoking is a huge environmental risk factor of lung cancer that
increases with number of cigarettes smoked and the duration of the smoking
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history. Cessation remains one of the most effective means of prevention and
reduces one’s risk of developing lung cancer approximately 3-fold [4]. In a study
following men born in the 1920’s, cancer risk was reduced to that of a nonsmoker if cessation was achieved by age 30 and was reduced by half if it was
achieved by the age of 50 [4].
Lung cancer is a particularly severe issue for Kentucky, which leads the
nation in incidence and deaths [1]. In addition, Kentucky carries the 2nd highest
incidence rate for all cancer diagnoses and deaths [1]. Furthermore, lung cancer
related medical expenditures are a huge burden on the healthcare system with
an estimated direct cost of 12.1 billion dollars in 2010, corresponding to
approximately 10% of total cancer-related expenses [5]. Clearly, lung cancer
research is of vital importance not only to improve management, but also to
improve diagnostic capabilities.

1.2

Current

practices

in

lung

cancer

diagnostics

and

management
The long-term goal of applying SIRM in lung cancer research is both to aid in
improved diagnostics and therapeutics for better management of lung cancer.
The cure rate for lung cancer remains woefully low despite new management
strategies for other types of cancers. These poor outcomes are largely due to
late diagnoses where surgery is not an option due to significant metastasis. Only
15% of tumors are localized and operable at the time of diagnosis, which carries
the best 5-year survival rate of 53.5% [1]. However, 5-year survival drops

2	
  	
  

precipitously to 26.1% and 3.9% for regional and distant diagnoses, respectively
[1]. Distant metastasis comprises the majority of diagnoses at 57% [1].
Adenocarcinomas of the lung carry the best prognosis with a 5-year survival rate
of approximately 60% for localized disease; however small-cell cancer prognosis
is poor even with a localized diagnosis (20.1%) [6]. The squamous and large cell
subtypes comprise roughly 20% and 5% of lung cancers, respectively, and there
is discrepancy over whether the prognosis of these subtype differ significantly
from adenocarcinoma [1].

1.2.1 Diagnosis.
As stated previously, much of the problem underlying poor lung cancer
survival is late diagnosis. When symptoms present, the tumor has usually
distantly metastasized, and screening historically has been largely ineffective.
However, a risk-benefit analysis of the ongoing national lung cancer screening
trial (NLST) indicated that low-dose computed tomography (LDCT) screening
was beneficial for a select group of patients [7]. Therefore, the American Cancer
Society recently issued recommendations for annual screening of people aged
55-75 years old who are current smokers or who have quit within the past five
years.
Diagnosis also involves a thorough evaluation of tumor stage that
incorporates the tumor size, invasion, number of lymph nodes involved, and
presence or absence of metastasis. This step is crucial in order to determine
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prognosis as well as surgical candidacy since surgery generally yields better
outcomes than radiation or chemotherapy.
NSCLC is staged according to the recently revised TNM staging system
laid out by Goldstraw et. al [8]. Stage I disease is diagnosed when the primary
tumor size is up to 5 cm in diameter with minimal invasion no further than the
main bronchus. No regional lymph node involvement or distant metastasis can
be present for this stage. Tumors greater than 7 cm in diameter are included in
stage II disease that have more extensive invasion and involvement of regional
lymph nodes not extending to the mediastinum, but without distant metastasis.
Both stage III and IV disease can involve primary tumors of any size with
extensive invasion and regional lymph node involvement; however, stage IV
includes distant metastasis. Accurate staging involves requires diligent surgical
dissection as well as proper histopathological examination and is essential for
prognosis and management.
This staging approach has recently been suggested and is in the process
of being implemented for SCLC. Historically SCLC was categorized into either
limited or extensive disease, which essentially referred to the presence or
absence of distant metastasis. The more detailed TNM staging system has been
validated for SCLC to improve prognostic value; however, management has
remained largely unchanged [8].
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1.2.2 Management
Lung cancer treatment is dependent on the stage at the time of diagnosis
as well as other general health factors of the patient that govern surgical
candidacy. Also, the treatment plan is typically defined for non-small cell lung
cancer (NSCLC) or small-cell cancer (SCC). For early stage (I and II) tumors
surgical resection, if possible, is the standard of care [9]. Lobectomy is commonly
done; however, recent evidence suggests that sublobar (e.g. wedge) resection
provides comparable outcomes. The standard of care for early stage inoperable
tumors is radiotherapy (RT), but has poorer outcomes (5-year survival 15-48%).
However, the use of stereotactic body RT (SBRT) is increasing for these
patients, as it yields better outcomes with substantially less toxicity for
surrounding tissues.
For advanced stage tumors, surgery is generally not an option, and
combined chemoradiotherapy is typically used as it yields better outcomes than
chemotherapy or radiotherapy alone. However, research is ongoing to determine
whether induction chemotherapy, i.e., shrinking the tumor mass before surgery,
may benefit a select patient population. For late stage NSCLC, platinum (Pt)
based chemotherapy is generally adopted. Bevacizumab, a VEGF binding drug
that inhibits angiogenesis, has also been recently combined with Pt-based
therapy to achieve better outcomes. There are also some drugs that are used for
tumors containing specific mutations. These include Crizotinib and Erlotinib,
which are ALK kinase and tyrosine kinase inhibitors, respectively.
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Finally, SCLC is typically managed with combined chemoradiotherapy for
limited disease (e.g., etoposide/cisplatin with radiotherapy) and chemotherapy
alone for extensive disease; however, these cancers carry a particularly grim
prognosis despite ongoing research.

1.3 Selenium nutrition and anti-cancer efficacy
1.3.1 Nutrition and toxicity
Selenium is an essential micronutrient and is incorporated into the ‘21st’
amino acid, selenocysteine [10]. Natural foods rich in selenium include Brazil
nuts, seafood, and organ meats, among others [11]. Most of these natural food
sources contain organic seleno-compounds such as selenomethionine as the
predominant selenium species. The composition of inorganic selenium such as
selenite and selenate in soil has large regional variation, which is propagated into
organic forms such as selenomethionine through plant metabolism [12]. Selenite
and selenate as well as organic forms are also available in the form of nutritional
supplements. Selenium is utilized primarily in the redox reactions of enzymes like
glutathione peroxidase and thioredoxin reductase by functioning similarly to a
thiol. Selenium deficiency can lead to a constellation of symptoms including
cardiomyopathy, weakened immune response, thyroid abnormalities, and bone
deformities [13, 14]. Kashin-Beck disease is a well-characterized selenium
deficiency endemic to China that involves cardiovascular disease and bone
deformities [15]. However, selenium compounds can also be toxic at high doses
(selenosis) and leads to brittle nails, hair, and skin abnormalities in humans due
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to chronic overconsumption [16]. Selenosis is typically more of a problem in
livestock than in humans.

1.3.2 Selenium compounds possess anti-cancer activity
Selenium

has

a

long

history

in

cancer

research

as

both

a

chemopreventive and chemotherapeutic agent. A large number of organic and
inorganic seleno-species exist, such as methylseleninic acid (MSA) or selenite,
which are cytotoxic to cancer cells. It is important to differentiate the various
seleno-compounds outside of the umbrella term, selenium, due to a large
variation in anti-cancer and chemopreventive efficacy. MSA has been studied
extensively in prostate cancer and has been linked to decreased expression of
prostate specific antigen [17-19]. Apoptosis has also been observed for prostate
cancer cells treated with MSA [20]. Selenite also induces apoptosis in cancer
cells including lung adenocarcinoma A549 cells and rodent models [21].
Recently, selenite was shown to cause ROS mediated autophagy in A549 cells
by Park et al. [22]. Fan et al. has demonstrated the use of stable isotoperesolved metabolomics (SIRM) combined with transcriptomics for probing
metabolic alterations caused by selenite [23]
Despite these findings, however, the mechanism behind selenite toxicity is
only partially understood. The prevailing theory of selenite toxicity involves
successive reductions of selenite, eventually to some selenide species,
generating toxic ROS in a process that causes damages to DNA and other cell
machinery leading to death [24, 25].
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1.3.2.1 Chemopreventive clinical trials
Selenium supplementation has been the subject of several clinical trials
that yielded mixed results. The double-blind clinical trial by Clark et al. showed a
statistically significant decrease in prostate cancer incidence with a selenized
yeast supplementation [26]. Selenized yeast comprised of a mixture of seleniumcontaining compounds. Unfortunately, the large scale SELECT trial (selenium
and vitamin E cancer prevention trial) was prematurely terminated due to slightly
increased cancer incidence with selenium supplement among the participants
(reviewed in [27]). These results were disappointing; however, they are difficult to
interpret due to the choice of the selenium agent, selenomethionine (SeM). SeM
alone has very low cytotoxicity based on our findings and its cytoxicity is
enhanced only when combined with the methionine lyase treatment, which was
missing in the SELECT trial [28]. Therefore, further mechanism-based research
is necessary in order to determine the optimal choice of selenium-based
chemoprevention and/or therapy.

1.4 Cancer is a metabolic disease
1.4.1 The Warburg effect
Historically, altered metabolism in cancer was established in the early 1920’s
by Warburg [29]. In an elegant experiment, he demonstrated that even under
normoxic conditions, the rate of glucose utilized by tumor tissue for lactic
fermentation was ten times that used for aerobic respiration. Glycolytic
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stimulation, i.e., the “Warburg effect”, has since been established as a hallmark
of human tumors. Warburg actually postulated that stimulated glycolysis was the
fundamental origin for tumorigenesis; however, the Warburg effect is now
considered as one of the many metabolic consequences of accumulated
mutations that enable the anabolic and energetic requirements for tumor growth.

1.4.1.1 Clinical manipulations of the Warburg effect
The Warburg effect is so prevalent among cancers that it is routinely used for
cancer diagnostics by measuring the uptake of 2-deoxy-2-18F-D-glucose into
suspected tumor tissues using positron emission tomography (PET) scanning.
Increased rate of glycolysis has also been studied as a potential target for
chemotherapy. 2-deoxyglucose is a hexokinase inhibitor that showed promise
pre-clinically; however, the clinical trial yielded disappointing results [30].
Recently, 3-bromopyruvate (3BP) has been investigated in in vitro and in vivo
experiments [31]. 3BP has shown low non-cancer toxicity and high selectivity for
the inhibition of glyceraldehyde 3-phosphate dehydrogenase. Furthermore, the
potent 6-Phosphofructo-2-kinase (PFKB3) inhibitor, PFK15, has generated very
favorable results and is entering phase I clinical trials [32].

1.4.2 Tumors require increased anabolism and favorable energetics for
growth
In order to sustain the rapid and uncontrolled growth that defines cancer,
tumor cells need to increase their anabolism. By utilizing tracer-based
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experimental design, Fan et. al. have shown that non-small cell lung cancer
(NSCLC) tumors possess increased rates of glycolysis, Krebs’ cycle activity,
pyruvate carboxylase (PC) activity, and nucleotide synthesis [33]. Increased flux
through these pathways is vital to generating lipids, reducing equivalents, amino
acids, and nucleotides necessary for new biomass production. The high rate of
nucleotide synthesis that must occur to generate nucleic acids for rapidly growing
cancer cells has led to the use of anti-metabolites such as thioguanine, 5fluorouracil, and methotrexate as chemotherapeutics.

1.4.2.1 Altered metabolism is caused in part by the loss of tumorsuppressor genes and the activation of oncogenes
Changes of metabolic regulation in human cancer have been an important
focus of biomedical research and have been shown to be induced by a
combination of genetic mutations and altered expression of transcriptional
factors. These factors include increased transcription of MYC, increased activity
of the transcription factor NF-κB, the protein kinase AKT, and stimulation of the
mammalian target of rapamycin (mTOR) and mitogen-activated protein kinase
signaling pathways, among many others [34]. For glycolysis in particular, a
combination of the loss of the tumor suppressor gene phosphatase and tensin
homolog (PTEN) and activation of AKT and mTOR signaling cascades increases
hypoxia-inducible factor 1α (HIF-1α) activity. HIF is stabilized under hypoxic
conditions and positively regulates nine out of the 10 enzymes of glycolysis [35].
Also associated with elevated HIF-1 activity is the increase in glucose
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transporters (GLUTs) to supply accelerated glycolysis [36]. Interestingly, many
tumors also express the fetal M2 form of pyruvate kinase (PKM2). PKM2 binds to
tyrosine-phosphorylated proteins, which in turn removes the positive regulation
imposed by fructose-1,6-bisphosphate [37]. These events have the effect of
diverting glucose for anabolic processes such as nucleotide metabolism by
increasing the flux through the pentose phosphate pathway.
Gln is another essential nutrient for rapidly growing tumors as
glutaminolysis is an important anapleurotic input for the TCA cycle and
regeneration of anabolic precursors. Gln is converted to Glu enzymatically via
glutaminase (GLS), which is up-regulated by expression of the proto-oncogene
MYC [38]. Gln consumption is often increased in tumors and glutaminase (GLS)
inhibition has been shown to induce apoptosis in kidney and lung cancer cells,
which overexpress MYC to drive GLS expression [39].

1.4.2.2 Mutations of specific metabolic enzymes characterize certain
familial cancers
Interestingly, several familial cancers are associated with deficiencies of
the TCA cycle enzymes fumarate hydratase (FH) or succinate dehydrogenase
(SQR). Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is
characterized by a germline mutation and loss of function of the gene expressing
FH, followed by a profound rearrangement of TCA cycle metabolism [40]. SQR
deficiency, again caused by germline mutation, is associated with both renal
cancer and gastrointestinal stromal tumors (GIST) [41].
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1.4.3 O-GlcNAc modification of protein targets is increased in cancers
Uridine diphospho-N-acetyl glucosamine (UDP-GlcNAc) is a product of the
hexosamine biosynthetic pathway (HBP) that is used in the synthesis of
glycosaminoglycans, proteoglycans, and glycolipids [42]. UDP-GlcNAc is also the
substrate for O-GlcNAc transferase (OGT), which catalyzes the post-translational
modification of Ser and Thr residues in certain proteins [43, 44]. The expression
of OGT is increased in a variety of cancers including lung that correlates with
increased post-translational modification of protein targets [45, 46]. Furthermore,
targets are often co-regulated via phosphorylation with either synergistic or
competitive effects [47, 48]. These two modes of regulation are dynamic and can
even occur on the same residue.
UDP-GlcNAc biosynthesis is complex and incorporates intermediates from
glycolysis, the PPP, TCA cycle, glutaminolysis, and nucleotide synthesis.
Therefore, O-GlcNAcylation has been described as a nutrient sensor and
appears to regulate phosphofructokinase (PFK) by diverting glucose carbon
through the PPP under hypoxic conditions [49]. Interestingly, glucose starved
cancer cells maintain flux through the HBP and synthesis UDP-GlcNAc by
utilizing carbon from glycogen [50]. Other targets of OGT include OGT itself,
MYC, p53 and histones, among many others [51-54]. However, the functional
significance of the majority of these events is unclear.
Elucidation on the synthesis of UDP-GlcNAc from glucose and Gln is
essential to understanding upregulation of O-GlcNAcylation in lung cancer .
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Incorporation of glucose carbon into UDP-GlcNAc has been modeled by
Moselely et al. and this pathway is one focus of this study[55].

1.5 Rigorous analysis of the metabolic network requires a
systems-biochemical approach
In order to ascertain the breadth of metabolic changes that is induced by
either cancer transformation or a stressor such as an anti-cancer agent, one
must utilize an approach that is able to simultaneously measure the multitude of
metabolites that participate in many pathways.

1.5.1 Stable isotope-resolved metabolomics (SIRM)
SIRM is an approach that utilizes a tracer-based experimental design in
order to measure the incorporation of stable isotopes into metabolites. By
utilizing tracers like
and

15

13

C6-glucose or

13

C5,15N2-Gln, one can trace the flow of

13

C

N through glycolysis, PPP, HBP, TCA cycle, nucleotide biosynthesis, lipid

biosynthesis, and glutaminolysis by measuring the different combinations of
mass isotopologues or positional isotopomers that are generated for a given
metabolite (Figs. 2.6, 2.14, 2.18, 4.15). Isotopolgues and positional isotopomers
both refer to structures that differ in isotopic composition; however, positional
isotopomers refers to the positional location of the isotope, e.g.,

13

C1-lactate has

three distinct positional isotopomers. One can then begin to reconstruct the
metabolic network and assess flux through specific pathways. By understanding
which pathways are affected by a given stressor, one can then follow up with
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more specific and complimentary analyses such as enzymatic activity assays,
immunoblot, or qPCR in order to determine why and how a pathway is altered.
The use of stable isotopes offers several important advantages over
radioisotopes, including elimination of biohazard risk and ready detection by both
NMR and MS. The incorporation of stable isotopes into a metabolite will not
significantly alter its enzymatic transformation with respect to an unlabeled
metabolite. Although the kinetic isotope effect on enzyme reaction rate can occur
for different isotopes, this effect is largely negligible in

13

C or

15

N-based SIRM

because these isotopes have small relative mass change with respect to their
natural abundance atoms. Furthermore, the bond-breaking steps are usually not
rate-limiting within a pathway.
Fan et al. have utilized SIRM extensively to characterize metabolic
alterations in lung cancer [33, 55-60]. The use of nuclear magnetic resonance
(NMR) and mass spectrometry (MS) technologies are essential for SIRM and
offer complementary analyses. Nuclei such as

13

C and

15

N are observable by

NMR to provide structural information such as the position(s) of a heavy atom
within a give metabolite (isotopomer) based on the spin coupling patterns,
covalent linkage, and chemical shift information obtainable from NMR analyses.
MS readily differentiates different isotopologues due to their mass differences.
Furthermore, with the advent of Fourier transform-ion cyclotron resonance-mass
spectrometry (FT-ICR-MS), one can distinguish the tiny mass difference between
13

C and

15

N (e.g.

13

C1,15N0 and

13

C0,15N1) labeled species due to ultra-high mass

resolution and accuracy.
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Finally, one must not overlook the importance of bioinformatics for
systems-biochemical approaches. The enormously rich data sets coupled with
high-throughput analysis generated from metabolomic investigation make
efficient bioinformatics essential to data analysis for generating meaningful and
comprehensive conclusions or new hypotheses.

1.6 Rationale for this study
This study aims to test the hypothesis that the anti-cancer mechanism of
selenite can be elucidated, at least in part, by a thorough and rigorous metabolic
approach. Lung cancer is an important focus of study due to its prevalence and
high lethality worldwide, and especially in Kentucky. Metabolic reprogramming
elicited by oncogenic transformations is increasingly apparent in various types of
cancer. Thus a systematic metabolic approach utilizing SIRM is expected to
advance understanding in the diagnosis and management of lung cancer by
uncovering key reprogrammed events, which then can be targeted for therapy or
help uncover early detection markers. The use of individualized ex vivo lung
cancer tissues adds a translational element to this investigation and can offer an
exciting view of cancer metabolism from actual patients. Selenite is an excellent
candidate to probe lung cancer metabolism given its history of anti-cancer activity
and potential for chemoprevention. Further research into selenite’s mechanism of
action is imperative to help clarify the recently failed SELECT trial.
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CHAPTER 2-SELENITE INDUCES CANCERSPECIFIC CHANGES IN METABOLISM
2.1 Introduction
An emerging trademark of human tumors is increased O-linked
modification of proteins by N-acetylglucosamine (O-GlcNAcylation) [51].
Increased O-GlcNAcylation has been observed and reported in lung, colon, and
breast cancers in both pure cell culture and human tumors [45, 46, 61]. The
expression of the transfer enzyme responsible for this post-translational
modification, O-linked N-acetylglucosamine transferase (OGT) is increased in
these tissues and thus is likely responsible for the observed increase in GlcNAc
modification [45]. However, what has been lacking in these investigations is a
detailed study of the biosynthesis of uridine diphospho-N-acetylglucosamine
(UDP-GlcNAc), the GlcNAc donor and substrate of the transferase, in human
lung cancer associated-upregulation of GlcNAc modification.
UDP-GlcNAc is the nucleotide hexosamine that contributes GlcNAc for Olinked glycosylation. The synthesis of UDP-GlcNAc is a complex processes that
comprises multiple pathways including the pentose phosphate pathway,
hexosamine biosynthetic pathway, glutaminolysis, nucleotide biosynthesis,
Krebs’ cycle, and glycolysis. The connection of this metabolite to glucose and
glutamine metabolism has established UDP-GlcNAc synthesis as a nutrient
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sensor [47, 49, 62, 63].

As such, UDP-GlcNAc biosynthesis, including its

contributing metabolic pathways, needs thorough SIRM-based analysis to
determine the regulatory mechanisms underlying synthesis of this important
metabolite.
The utility of SIRM for the analytical dissection of cancer transformed lung
metabolism has been well established [33, 56, 58]. Furthermore, UDP-GlcNAc
biosynthesis in prostate cancer cells was previously modeled using a nonsteady-state algorithm and a SIRM based approach by Moseley et al. [55]. Here,
I expanded upon previous work reported by Fan et al. on metabolic alterations
induced by the anti-cancer agent selenite [60]. Our goal was to uncover a more
detailed mechanistic understanding of selenite-induced anti-cancer activity by
determining the time course enrichment of glucose and Gln derived metabolites
associated with the UDP-GlcNAc biosynthetic network and comparing these
profiles to an immortalized normal human bronchial epithelial (NHBE) cell line.
This approach was then repeated in parallel experiments utilizing NSCLC
surgical patient tumor and adjacent benign tissue. These individualized lung
cancer models offer a more realistic interpretation of the metabolic changes that
occur with exposure to selenite because they contain much of the tumor
infrastructure, including stromal cells as well as potentially tumor-suppressive
immune cells. Furthermore, these experiments are derived from actual NSCLC
patients and are thus representative of the variability of early-stage operable lung
cancer. However, the heterogenous cell population of this model is likely to
produce a more mixed set of results than those obtained from traditional
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monolayer cell culture. But, this approach also includes a measure of the
different metabolic adaptations that are likely to occur that support tumor growth
in actual humans. Finally, by comparing the individualized lung cancer models to
cell-based experiments one can begin to assess the power and/or limitations of
conclusions drawn from cell culture experiments.

2.2 Methods
Cell culture: A549 cells were grown in glucose-free, glutamine-free DMEM
medium supplemented with 10% FBS, 0.2% glucose, 4 mM glutamine, and 100
I.U./mL penicillin 100 µg/mLstreptomycin at 37 °C and 5% CO2. Na2SeO3
(Sigma) solutions were prepared immediately prior to use and sterilized using
0.22 µm syringe filter. Cells were grown to 70% confluence for all experiments.
Two hours prior to treatment, medium was aspirated and replaced with half
volume of the tracer medium containing either
Louis. MO) or

13

13

C6-glucose (Sigma Isotec, St.

C5,15N2-Gln (Cambridge Isotopes, Andover, MA). The remaining

medium was then added with doubled Na2SeO3 concentration in order for cells to
be conditioned with the tracer medium prior to treatment.

Tissue slices: During NSCLC surgical resection, very thin slices (0.5-1 mm) were
prepared from tumor and adjacent benign tissue by the operating surgeon (Dr. M.
Bousamra II). Tissue slices were immediately placed in T-25 culture flasks with 8
mL DMEM medium supplemented with 10% FBS, 100 I.U./mL penicillin 100
µg/mLstreptomycin, 0.2% glucose, and 4 mM Gln. Either

	
  
18	
  

13

C6-glucose or

13

C515N2-Gln was used for tracer experiments. Slice medium was then treated

with or without 6.25 µM Na2SeO3. Flasks were then placed on a rotator in a cell
culture incubator at 37 °C and 5% CO2 for 24h. After 24h, medium was collected
for downstream analysis, and tissue slices were washed with PBS before flash
freezing in LN2.

Proliferation assays: Proliferation of A549 cells was measured in 96-well plates
according to the protocol by Raspotnig et al. [64]. Briefly, 24 h after treatment
with selenite, cell medium was aspirated and replaced with 50% ethanol in H2O
for 30 min. Ethanol was then aspirated and replaced with minimal volume of
0.2% Janus green dye in PBS for 5 min. Dye was aspirated and plates were
rinsed in tap H2O and drained by gravity. Dye was then dissolved in 0.5 N HCl
and absorbance was measured at 595 nm. Growth was reported as the fraction
of the absorbance for a given concentration of selenite divided by the control
absorbance. Increasing concentrations of Na2SeO3 were used and the EC50
concentration was interpolated from the logarithmic transformation of the doseresponse curve. Growth did not reach 0% for the concentrations of Na2SeO3
used.

Extraction of metabolites: At the time of harvest, medium was collected before all
plates were washed three times with ice cold PBS, and PBS was removed as
much as possible by aspiration. The cells’ metabolism was then quenched with 1
ml of CH3CN kept at -20°C before 0.75 ml of nanopure water was added and
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cells were harvested by scraping. The process was repeated once before CHCl3
addition to a final CH3CN:H2O:CHCl3 ratio of 2:1.5:1 to obtain the polar, nonpolar and insoluble proteinaceous interface fractions for downstream analysis
[65, 66]. For metabolite extraction from the medium, protein was first precipitated
in ice-cold 10% trichloroacetic acid (TCA), and supernatant was lyophilized
immediately to remove the acid. Since some metabolites such as glutamine are
sensitive to prolonged storage in acidic conditions, metabolite analysis of
medium samples by NMR or GC-MS was performed immediately after
lyophilization.

NMR experiments: All NMR experiments were conducted on a Varian Inova 14.1
T instrument equipped with 5 mm HCN cold probe. Cell and medium extracts
were dissolved in D2O with 30 and 50 nmol d6-DSS, respectively, as internal
standard. Shigemi tubes were used for polar extracts to minimize sample volume
and thus to concentrate the metabolites. 1D proton spectra were recorded with
an acquisition time of 2 seconds after initial presaturation of the H2O signal with a
recycle time of 5 seconds. 1D

13

C-filtered HSQC spectra were measured using

an acquisition time of 150 ms. 1D proton spectra were processed using a 1 Hz
exponential line broadening function and a zero fill of 128 k points. 1D 13C-filtered
HSQC spectra were processed with a 6 Hz line-broadening exponential and 0.07
Hz Gaussian functions and zero filled to 16 k points. Both types of spectra were
processed manually for baseline and phase corrections. 1D proton spectra were
referenced using the methyl signal of D6-DSS at 0 ppm, and 1D
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13

C-filtered

HSQC spectra were referenced to the C3-lactate peak at 1.32 ppm and 1.41 ppm
for cell and medium extracts, respectively. Metabolites were identified in
reference to an in-house standard database and quantified by calibration with the
methyl resonance of the DSS internal standard using the MestReNova NMR
processing software (Mestrelab Research, Santiago de Compostela, Spain) [59].

GC-MS analysis: An aliquot of the lyophilized extracts was derivatized in 50% Ntert-Butyldimethylsilyl-N-methyltrifluoroacetamide

with

1%

tert-

Butyldimethylchlorosilane (MTBSTFA + 1% TBDMSCl) in CH3CN before GC-MS
analysis. All GC-MS data were acquired on a ThermoFinnigan PolarisQ GC-Ion
trap MSn instrument (ThermoScientific, Rockford IL). One µL of the derivatized
sample was separated on a SGE Forte (Victoria, Australia) 5% phenyl capillary
column with the following dimensions: 50 m x 0.15 mm; 0.25 µm film thickness.
The GC parameters were as follows: injector and transfer line, 280 °C; oven, 60
°C for 2 min, 60 to 150 °C at 20 °C/min ramp, 150 to 300 °C at 6 °C/min ramp;
He carrier gas with flow rate of 1.5 mL/min. Spectra were acquired in segscan
mode with ranges of 140-206, 209-280, and 283-650 m/z with an acquisition time
of 0.97 s. Spectra were processed using Xcalibur MS software and quantified
using a mixture of 63 standards at 50 µM each except for glutamate at 500 µM.
All samples and standards were spiked with 1 µM norleucine as internal
standard.
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Nucleotide

processing

for

FT-ICR-MS

(Fourier

transform-ion

cyclotron

resonance-mass spectrometry) analysis: Nucleotides were ion-paired with
hexylamine and extracted from polar extracts as described previously [57].
Briefly, dried extract aliquots (e.g. 1/16 of one 10 cm plate) were dissolved in 5
mM hexylamine in H2O (buffer A) with the pH adjusted to 6.3 with acetic acid.
Dissolved nucleotides were adsorbed onto C18 ZipTips (Millipore, Billerica, MA)
pre-conditioned with MeOH and buffer A. Bound nucleotides were then washed
with buffer A followed by elution with 70% buffer A/30% buffer B (90% methanol
and 10% 10mM ammonium acetate adjusted to pH 8.5 with aqueous ammonia).
Eluent was then lyophilized and reconstituted in 2:1 MeOH:buffer B for FT-ICRMS analysis.

FT-ICR-MS analysis: FT-ICR-MS analysis was performed as described
previously [57]. Briefly, data were recorded on a hybrid linear ion trap–FT-ICR
mass spectrometer (Finnigan LTQ FT, Thermo Electron, Bremen, Germany)
using an automated nanospray ion source (TriVersa NanoMate, Advion
BioSciences, Ithaca, NY) set with an “A” chip run at 1.5 kV and 0.5 psi head
pressure. Measurements were recorded for 15 min, which consisted of 14 min of
high resolution FT-ICR scans, followed by 30 s of low resolution ion trap scans
(LTQ). FT-ICR-MS scans were recorded from 150-800 Da with a mass resolving
power set to 400,000 at 400 m/z. At this resolution and mass accuracy the mass
difference between 12C1,15N1 and 13C1,14N1 is resolved and therefore can be
independently measured in a double labeling experiment. Each transformed
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spectrum consisted of 5 summed transients at 2 s per transient for a cycle time of
10 s. All FT-ICR-MS scans were summed to produce the final spectrum. Spectra
were then exported via Xcalibur MS software and peaks were corrected and
assigned using an in-house software (PREMISE [56]).

Western Blot: At time of harvest cells were lysed directly on the plate using 62.5
mM Tris, 2% SDS buffer at pH 6.8 before harvest by scraping, and protein
concentration was measured via the BCA method (Pierce). All protein extracts
were diluted in 4X loading buffer (50% glycerol, 4% SDS, 150 mM Tris pH 6.8, 1
mM DTT, 0.02% bromophenol blue, 10% β-mercaptoethanol) to 1X strength and
then boiled for 10 minutes prior to electrophoresis. Approximately 30 µg protein
was loaded for each sample onto a denaturing SDS 10 % acrylamide gel with a
6% stacking gel. Protein extracts were stacked for 30 min at 100 V and then
resolved for 1.5 h at 200 V using commercially available Tris/Gly/SDS buffer
(National Diagnostics, Atlanta, GA). Proteins were then transferred onto a PVDF
membrane (Immobilon-P, Millipore, Bedford, MA) at 25 V for 2 h at room
temperature in an Invitrogen transfer apparatus All primary antibodies were
incubated with membrane at 4 °C on a rocker overnight as follows: β-o-linked N-acetylglucosamine (Sigma, St. Louis, MO), 1:1000 in PBST with 5% BSA; αtubulin (epitomics), 1:50,000 in PBST with 5% non-fat powdered milk.
Membranes were then washed 3 times with PBST before incubating 1 hour at
room temperature with an HRP-conjugated secondary antibody (Pierce, 1:2000
in PBST with 5% non-fat powdered milk). Blots were then incubated in Pierce
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supersignal extended duration chemiluminescent reagent before exposure to xray film (SCBT) for visualization.

GAIMS analysis: GAIMS deconvolution was performed by Dr. Hunter Moseley as
described previously [55]. FT-ICR-MS measurements from the selenite time
course of A549 were used to identify UDP-GlcNAc isotopologue intensities. Each
isotopologue intensity represents combinations of 13C6-glucose, 13C5-ribose, 13C2acetyl, and/or

13

C1 ,

13

C2, and 13C3-uracil groups in the UDP-GlcNAc molecule.

Solutions to the equations generated from these combinations are then solved
via the algorithm.

Statistical analysis: All metabolite amounts were normalized to total protein
measured via BCA method. All error bars represent the standard deviation of an
average of experiments (specific number of experiments detailed in appropriate
figure legends). For statistical significance, the two-tailed Student paired t-test
was used to calculate p values. Significance was assumed for p values less than
0.05. For experiments involving multiple measurements (i.e., measurement of
metabolites from NMR and MS analysis) the false discovery rate method
described by Benjamini and Hochberg was applied [67]. Briefly, naïve p-values
for all measured metabolites were calculated. These values were then ranked in
order of decreasing significance and assigned a rank number. A qi value was
then calculated according to the equation qi=kpi/i where i=rank of the p value
among the k tests. The false discovery rate (FDR) was then defined for every qi
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value such that FDRi=min(qi,…,qk). Tests with p values <0.05 and an FDR value
<0.05 were then accepted as significant. The following analytes were measured
and included for statistical analysis via FDR: citrate, fumarate, malate, Asp,
lactate, glucose, Ser, Ala, UDP-GlcNAc, UTP, ATP, and lactate.

2.3 Results and discussion
2.3.1 Selenite induces dose-dependent cell death in human lung cancer
models
2.3.1.1 Cell culture
In order to determine an appropriate treatment concentration of Na2SeO3
for subsequent tracer experiments, the dose-response curve was first
established in A549 cells, and changes in cell morphology were measured using
phase contrast microscopy as shown in figure 2.1. The EC50 calculated from the
curve in figure 2.1A was 6.25 µM for 24 h of treatment. Prominent morphological
features of A549 cells treated with 6.25 µM Na2SeO3 are illustrated in figure
2.1B. Features specific to the treated cells included the widespread appearance
of vacuolar inclusions within the cytoplasm by 6 hours. By 24 hours, these
vacuoles had diminished in number but were still present. These vacuoles have
been reported as autophagosomes by Park et al. [22]. Cell detachment was also
visually more prominent in treated cells than in controls. Also, treated cells were
noticeably less confluent.
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Figure 2.1. Selenite effect on A549 proliferation and morphology
A) A549 cells were treated for 24 h with increasing concentrations of Na2SeO3, and growth was
measured via Janus green assay. Growth was plotted as the percentage absorbance of
selenite/CTL. B) A549 cells were treated with or without 6.25 µM Na2SeO3, and images were
recorded on a phase contrast microscope. Arrows indicate vacuolar inclusions (expanded in
inset).
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2.3.1.2 Human tissue slices
Thin (0.5-1 mm) slices of tumor and adjacent benign lung tissue from
NSLSC surgical patients were also used as an individualized model for human
lung cancer in parallel with the following cell experiments. These tissue slices are
analogous to those described by Warburg [29], but are placed in medium rather
than on wet blotting paper, thereby giving much greater control over nutrient
supply and removal of waste products. Such slices represent better models than
cultured cells as they contain much of the in situ microenvironment that is lost
with cell cultures. In order first to establish that these tissue slices were
metabolically viable 24 hours ex vivo, we incubated both cancerous and adjacent
benign lung tissue with

13

C6-glucose tracer, as described. As indicated by the

appearance of 13C-1’-AXP satellite peaks at 6.28 and 5.98 ppm in figure 2.2, both
the cancerous and benign lung tissue slices had synthesized AXP from

13

C6 -

glucose at the time of harvest. We then treated the slices with 6.25 µM Na2SeO3
for 24 h as in the cell experiments and afterwards prepared sections for
histological hematoxylin and eosin (H&E) staining to measure any morphological
changes. Surprisingly, we found that selenite induced widespread necrosis in the
tumor tissue that was not observed in the adjacent benign tissue (Fig. 2.3). I thus
chose to use 6.25 µM Na2SeO3 as the treatment concentration for all subsequent
tracer experiments based on the dose response of A549 and its efficacy in
inducing cancer cell death in the tissue slices.
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Figure 2.2. Metabolic viability of benign and tumor tissue slices from NSCLC surgical
patients
Tissue slices were prepared from resected tumor and adjacent benign lung tissue of NSCLC
13
13
patients and incubated for 24 hours with C6-glucose tracer. C-1’-AXP satellite peaks (6.28 and
13
5.98 ppm) flanking the central 1’-AXP peak at 6.14 ppm indicate incorporation of C6-glucose
into the ribose subunit of AXP and active AXP synthesis.
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Selenite

Benign

Selenite

Figure 2.3. Selenite induces necrosis in human lung tissue slices
Representative hematoxylin and eosin stained histology images from selenite treated tissue
slices. Tissue slices prepared from resected tumor and adjacent benign lung tissue of NSCLC
patients were incubated for 24 h with or without 6.25 µM Na2SeO3 and prepared for histological
staining.
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2.3.2 Selenite effects on polar metabolites
A549 cells were grown in medium containing

13

C6-glucose tracer and

treated with selenite as described above. Polar metabolites were then extracted
and measured via 13C-filtered 1D HSQC NMR after harvesting the cells to assess
selenite-induced perturbations (Fig. 2.4). These spectra indicate protons directly
attached to

13

C atoms and thus represent de novo biosynthesis from labeled

tracers. Many metabolic pathways were affected by selenite treatment as
indicated by differences in the amounts of newly synthesized intermediates. As
shown by the peak at 1.32 ppm,

13

C-3-lactate increased in selenite-treated A549

cells but not in NHBE cells, suggestive of an increase in glycolytic flux or
increased diversion of pyruvate into lactate at the expense of other metabolites.
There were also numerous polar metabolites that decreased in the treated cells
especially

13

C-3-Ala,

13

C-4-Glu,

13

C-4-Glu-glutathione,

13

C-2,5-citrate, and

13

C-3-

Asp at 1.46, 2.34, 2.54, 2.66, and 2.8 ppm, respectively, indicating decreased
amino acid synthesis and TCA cycle activity from glucose. In order to determine
if these selenite-induced changes were cancer cell specific, I then treated
immortalized NHBE cells with 6.25 µM Na2SeO3 and measured the polar
metabolites as shown in figure 2.4. Interestingly, the majority of the differences
observed in A549 were absent or minimal in NHBE suggesting cancer cell
specificity.
I then examined the polar metabolite profile of selenite-treated tumor and
benign tissue slices as shown in figure 2.4. Many of the metabolic alterations
noted in A549 were recapitulated in the cancer tissue slices including decreased
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Cancer

Benign

13

Figure 2.4. Selenite effect in C6-glucose labeled polar metabolites
13
Specified cell lines or tissues were treated with 6.25 µM Na2SeO3 for 24 h with C6-glucose
13
tracer. Polar metabolites were extracted and measured via C-filtered 1D HSQC NMR. Treated
and control spectra were superimposed and normalized to total mg protein in order to visualize
differences.

	
  
31	
  

13

C-3-Ala,

13

C-4-Glu,

with increased

13

13

C-4-Glu-glutathione,

13

C-2,5-citrate, and

13

C-3-Asp along

C-3-lactate. In contrast, with the exception of lactate, other

metabolites in the benign tissue showed much smaller effects with selenite
treatment, analogous to the comparison between A549 and NHBE cells, again
suggesting cancer specificity.
We then repeated the same experiments using

13

C5,15N2-Gln in order to

determine the effect of selenite on metabolites derived from the anapleurotic
precursor Gln (Fig. 2.5). Again, selenite induced a striking depletion of Krebs’
cycle intermediates

13

C-2,5-citrate and

and tumor tissue. Interestingly,

13

13

C-3-Asp in selenite-treated A549 cells

C-4-Glu decreased while

13

C-4-Gln increased,

in both treated A549 cells and treated cancer tissue. However, there were
substantially fewer differences between the selenite and control groups in the
NHBE and benign tissue counterparts. Notably,

13

C-4-Glu-glutathione was also

reduced by selenite treatment. A more detailed investigation of selenite effects
on glutaminolysis is explored in chapter 3.
2.3.3 Selenite decreases TCA cycle activity
In order to more fully explore selenite-induced TCA cycle disturbances, I
then measured the time course of enrichment of

13

C6-glucose-derived Krebs’

cycle isotopologues. By understanding defined reaction mechanisms, one can
trace the flow of

13

C atoms through central metabolic pathways, as illustrated in

figure 2.6, when a time course design is employed.

13

C6-glucose generates

13

C2 -

acetyl-CoA as it is metabolized through glycolysis and pyruvate dehydrogenase.
When 13C2-acetyl-CoA condenses with unlabeled oxaloacetate, 13C2-citrate is
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Cancer

Benign

13

15

Figure 2.5. Selenite effect in C5, N2-Gln labeled polar metabolites
13
15
Specified cell lines or tissues were treated with 6.25 µM Na2SeO3 for 24 h with C5, N2-Gln
13
tracer. Polar metabolites were extracted and measured via C-filtered 1D HSQC NMR. Treated
and control spectra were superimposed and normalized to total mg protein in order to visualize
differences.
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Citrate
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Oxaloacetate

Fumrate

Malate

13

Figure 2.6. C flow through glycolysis, PDH, and the TCA cycle
13
13
13
Filled circles represent C atoms. C6-glucose is transformed into C2-acetyl-CoA, and then
doubly labeled Krebs’ cycle intermediates as it is metabolized through glycolysis, PDH, and the
TCA cycle.
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generated. As shown in figure 2.7A, the depletion of

12

C6-citrate was slower in

selenite treated A549 cells than in controls and had plateaued by 10 hours of
treatment. Conversely, 13C2-citrate increased more rapidly and to a higher level in
controls relative to selenite. This implies that glucose is providing less carbon to
the Krebs’ cycle in the presence of selenite, consistent with the observed
diversion to lactate shown in figure 2.4. When these same isotopologues were
measured in immortalized NHBE cells that were treated with selenite for 24 hours
under the same conditions as A549, the differences between control and selenite
were not significant (Figs. 2.7C and D). Finally, we measured

13

C0 and

13

C2 -

citrate in tumor and adjacent benign tissue slices from four separate NSCLC
surgical patients. These tissue slices were cultured in

13

C6-glucose, treated with

or without selenite, and processed similarly to the A549 and NHBE cells.
Analogous to the cell culture models, we found that

13

C2-citrate was significantly

reduced in the cancer tissue compared to controls (Fig. 2.7E and F).

13

C0-citrate

was not increased to compensate for the selenite-induced reduction in

13

C2 -

citrate due to an increase in 13C1-citrate. However, no significant differences were
seen between treatments in the benign tissue.
13

and

13

C2-citrate is then transformed into

13

C2-α−ketoglutarate,

13

C2-succinate,

C2-fumarate as it is metabolized through the TCA cycle. When

13

C0 -

fumarate and 13C2-fumarate were measured as above in A549 cells, we observed
the same isotopologue patterns as in citrate (Figs. 2.8A and B). Fumarate
enrichment was unaltered by selenite treatment in the treated NHBE group (Figs.
2.8C and D). When tissue slices were examined, fumarate enrichment was
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13

Figure 2.7. Effect of selenite on C6-glucose enrichment of citrate in A549, NHBE, and
human tissue slices
13
A and B) A549 cells were pre-incubated for 2 hours with C6-glucose followed by treatment with
or without 6.25 µM Na2SeO3. Harvest hour denotes time after treatment. C and D) NHBE cells
13
were cultured in C6-glucose supplemented medium and treated with or without 6.25 µM
13
Na2SeO3 for 24 hours. E and F) Patient tissue slices were cultured in C6-glucose supplemented
medium and treated with or without 6.25 µM Na2SeO3 for 24 hours. Polar metabolites from all
experiments were extracted and citrate was quantified via GC-MS and normalized to total protein.
*p<0.005; n=4.
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13

Figure 2.8. Effect of selenite on C6-glucose enrichment of fumarate in A549, NHBE,
and human tissue slices
13
A and B) A549 cells were pre-incubated for 2 hours with C6-glucose followed by treatment
with or without 6.25 µM Na2SeO3. Harvest hour denotes time after treatment. C and D) NHBE
13
cells were cultured in C6-glucose supplemented medium and treated with or without 6.25 µM
13
Na2SeO3 for 24 hours. E and F) Patient tissue slices were cultured in C 6-glucose
supplemented medium and treated with or without 6.25 µM Na2SeO3 for 24 hours. Polar
metabolites from all experiments were extracted and fumarate was quantified via GC-MS and
normalized to total protein. *p<0.01; n=4.
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significantly decreased by selenite treatment specifically in the tumor tissue
(Figs. 2.8E and F).
13

C2-fumarate is then converted via fumarase to 13C2-malate, which is also

measurable via GC-MS. The isotopologue distribution of malate reiterated the
same pattern described of citrate and fumarate as illustrated in figure 2.9. Finally,
13

C2-malate is converted to

metabolic fate of

13

13

C2-oxaloacetate via malate dehydrogenase. One

C2-oxaloacetate is transamination to

13

C2-aspartate. I

measured the aspartate isotopologue distribution as another analogue of TCA
cycle activity, which reflected the same changes described for citrate, fumarate,
and malate (Fig. 2.10). Taken together, selenite induced a profound decrease in
the doubly labeled Krebs’ cycle intermediates citrate, fumarate, malate, and
aspartate in A549 lung cancer cells. These changes were specific to A549
relative to immortalized NHBE cells. Interestingly,

13

C2-malate appeared to be

slightly increased with selenite treatment in NHBE. These findings were then
recapitulated in the individualized lung cancer tissue slice model indicating a
cancer specific decrease in the flux through the TCA cycle caused by selenite.
2.3.4 Selenite stimulates glycolysis in A549
One immediately obvious feature from the selenite-treated A549 spectra in
figure 2.4 was increased
13

13

C-3-lactate.

C6-glucose can in turn generate

13

13

C3-pyruvate generated via glycolysis of

C3-lactate through lactate dehydrogenase.

This process restores oxidizing equivalents for substrate level phosphorylation by
replenishing NAD+ and is a hallmark of tumor metabolism [29]. However,
intracellular lactate, which is illustrated in figure 2.4 at 1.32 ppm, represents only
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13

Figure 2.9. Effect of selenite on C6-glucose enrichment of malate in A549, NHBE, and
human tissue slices
13
A and B) A549 cells were pre-incubated for 2 hours with C6-glucose followed by treatment with
or without 6.25 µM Na2SeO3. Harvest hour denotes time after treatment. C and D) NHBE cells
13
were cultured in C6-glucose supplemented medium and treated with or without 6.25 µM
13
Na2SeO3 for 24 hours. E and F) Patient tissue slices were cultured in C6-glucose supplemented
medium and treated with or without 6.25 µM Na2SeO3 for 24 hours. Polar metabolites from all
experiments were extracted and malate was quantified via GC-MS and normalized to total
protein.
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13

Figure 2.10. Effect of selenite on C6-glucose enrichment of Asp in A549, NHBE, and
human tissue slices
13
A and B) A549 cells were pre-incubated for 2 hours with C6-glucose followed by treatment with
or without 6.25 µM Na2SeO3. Harvest hour denotes time after treatment. C and D) NHBE cells
13
were cultured in C6-glucose supplemented medium and treated with or without 6.25 µM
13
Na2SeO3 for 24 hours. E and F) Patient tissue slices were cultured in C6-glucose supplemented
medium and treated with or without 6.25 µM Na2SeO3 for 24 hours. Polar metabolites from all
experiments were extracted and malate was quantified via GC-MS and normalized to total
protein. *p<0.05; n=4.
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a small fraction of the total lactate produced as most of the lactate generated
from anaerobic fermentation is exported from the cell. Therefore, I also measured
extracellular lactate production by quantifying the time course lactate
isotopologue distribution in the media of

13

C6-glucose labeled A549 as shown in

figure 2.11. The medium measurements reiterated the cellular measurements
and showed a substantial increase in

13

C3-lactate production in selenite-treated

media suggestive of increased utilization of glucose for lactate at the expense of
acetyl-CoA (Fig. 2.11B). In order to determine whether or not increased lactate
synthesis is indicative of an increase in flux through glycolysis, one must
consider the rate of glucose consumption as shown in figure 2.12. Linear
regression analysis of lactate production and glucose consumption indicated ~4
and ~2-fold increases, respectively, in selenite-treated cells (Table 2.1). These
values are consistent with a selenite-induced increase in glycolytic flux along with
reallocation of glucose carbon for lactate synthesis at the expense of TCA cycle
intermediates as further illustrated in figure 2.13.
Selenite-induced stimulation of lactic fermentation is likely compensating
for reduced TCA cycle activity evidenced by the attenuated

13

C2 intermediates

discussed above. Interestingly, selenite-treated A549 media also accumulated
13

C2-lactate. A variety of labeling patterns of lactate can be generated through

two rounds of the TCA cycle and malic enzyme catalyzed conversion of malate to
pyruvate followed by lactate production via lactate dehydrogenase as depicted in
figure 2.14. If pyruvate is generated from doubly labeled malate via malic
enzyme, then the isotopologue distribution should be 13C2:13C1 1:1. However,
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Figure 2.11. Effect of selenite on lactate production in A549
13
A549 cells were pre-incubated for 2 hours with C6-glucose followed by treatment with or without
13
13
6.25 µM Na2SeO3. Harvest hour denotes time after treatment. C2 (A) and C3 (B)-lactate
isotopologues were quantified via GC-MS from medium aliquots taken from the onset of
treatment (0 h) and at cell harvest. 0 h values were subtracted from harvest hour values and the
resulting quantity was normalized to total protein to calculate the amount of lactate produced.
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Figure 2.12. Effect of selenite on glucose consumption in A549
13
C6-glucose was quantified from 1D proton NMR spectra generated from medium aliquots taken
13
at the onset of treatment (0h) and at cell harvest. Cells were pre-incubated with C6-glucose
tracer for 2 hours before treatment with 6.25 µM Na2SeO3. 0h values were subtracted from
harvest hour values and the resulting quantity was normalized to total protein.
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Table 2.1 Linear regression analysis of lactate production and glucose consumption in
selenite-treated A549 cells
Linear regression was applied to data from figures 2.11 and 2.12, and the above variables were
calculated. Slopes of selenite-treated cells were significantly different from non-treated controls
13
13
with p values <0.0005 for both C3-lactate production and C6-glucose consumption.

Figure 2.13. Effect of selenite glucose carbon allocation to lactate
13
13
C6-glucose and C3-lactate were quantified from 1D proton NMR spectra generated from
medium aliquots taken at the onset of treatment (0h) and at cell harvest. Cells were pre-incubated
13
with C6-glucose tracer for 2 hours before treatment with 6.25 µM Na2SeO3. 0h values were
subtracted from harvest hour values for glucose, and lactate was divided by glucose consumed to
determine the fraction of glucose converted to lactate. Values were then normalized to mg
protein.
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13C

Fumarate

6-Glc

Glycolysis
and PDH

Malate

!-Ketoglutarate

Malic
enzyme

Acetyl CoA
Oxaloacetate

Citrate
Pyruvate

!-Ketoglutarate

TCA cycle

Citrate

Acetyl CoA

Oxaloacetate

malic
enzyme

Fumarate

Malate

13

Lactate

Pyruvate

Figure 2.14.
C flow through glycolysis, TCA cycle, malic enzyme, and lactate
dehydrogenase
13
13
As C6-glucose is metabolized through glycolysis and the TCA cycle eventually symmetric C213
13
fumarate is generated, which generates two distinct C2 isotopomers of malate. If C2-malate is
13
13
decarboxylated via malic enzyme to pyruvate, C2 and C1-pyruvate should be created in equal
amounts. If doubly labeled malate continues through another round of the TCA cycle with doubly
13
13
labeled acetyl-CoA, then C2 and C3 pyruvate will be generated a ratio of 3:1. Generation of
lactate from labeled pyruvate will create the isotopomer distribution displayed above. Blue filled
13
circles represent C atoms. Functional groups have been removed from all structures to simplify
13
C flow.
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very little

13

C1 was measured in the media. If doubly labeled malate undergoes

another round of TCA cycle conversions with doubly labeled acetyl-CoA, then a
predominance of

13

C2-lactate will eventually be generated. Therefore, when the

possibilities of lactate generation from glycolysis and malic enzyme (ME) are
taken into consideration, a predominance of
However, it is puzzling that

13

13

C2 and

13

C3-lactate will be formed.

C2-lactate would accumulate in selenite-treated

cells, since TCA cycle activity is reduced and lactate production from Gln
appears to be negligible. However, if malic enzyme activity is increased upon
selenite treatment, doubly labeled Krebs’ cycle intermediates could be siphoned
off for lactic fermentation ultimately reducing the amounts of measurable

13

C2

intermediates. Notably, ME was indeed increased by selenite treatment at the
mRNA level as reported by Fan et al. [60].
As another measure of glucose utilization, we measured the serine
isotopologue distribution in selenite-treated A549 and NHBE cells.
is eventually converted through glycolysis to

13

13

C6-glucose

C3-3-phosphoglycerate, which is a

biosynthetic precursor for serine.13C3-Ser enrichment in treated A549 cells was
increased relative to controls; however, no differences were noted in treated
NHBE cells, which is again consistent with an increase allocation of glucose
carbon to lactate (Fig 2.15). These patterns indicate selenite induces a cancerspecific increase in glycolysis, which is likely a compensatory mechanism for
decreased flux through the TCA cycle.
Finally, I measured both the cellular and extracellular alanine isotopologue
distributions as another glycolytic analogue. Alanine can be synthesized from
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13

Figure 2.15. Effect of selenite on C6-glucose derived enrichment of serine in A549 and
NHBE
13
A and B) A549 cells were pre-incubated for 2 hours with C6-glucose and treated with or without
13
6.25 µM Na2SeO3. C and D) NHBE cells were cultured in C6-glucose supplemented medium
and treated with or without 6.25 µM Na2SeO3 for 24 hours. Polar metabolites from all experiments
were extracted and Ser was quantified via GC-MS and normalized to total protein.
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pyruvate through alanine transaminase, and an isotopologue distribution similar
to lactate is possible as shown in figure 2.14. Examination of the medium alanine
production indicated increased production of
production of

13

13

C3-Ala in controls and increased

C2-Ala in the treated A549 medium (Figs. 2.16A and B).

Quantification of cellular Ala reiterated these findings (Figs. 2.16C and D).
Selenite-increased

13

C2-Ala may arise from increased

previously. But in this scenario,

13

13

C2-lactate as discussed

C3-Ala was actually decreased in the selenite

group relative to controls. The data are puzzling; however, one possible solution
for this distribution would be a combination of increased malic enzyme and
lactate dehydrogenase activity. Increased flux through malic enzyme could
generate

13

C2

and

13

C3-pyruvate

in

selenite

treated

cells.

If

lactate

dehydrogenase activity were increased in order to replenish NAD+, then most of
the pyruvate would be siphoned off for lactate synthesis. Some of the doubly and
triply labeled pyruvate could generate correspondingly labeled alanine, which is
illustrated by the measured increase in
generating predominantly

13

13

C2-Ala. However, since the controls are

C3-Ala, the overall

13

C3-Ala enrichment is actually

greater than with selenite treatment. Taken together these data strongly indicate
that selenite increases glycolytic activity.
2.3.5 Selenite decreases nucleotide synthesis
In

an

ongoing

effort

to

characterize

selenite-induced

metabolic

perturbations, I then examined nucleotide synthesis. Analysis of the 1D proton
spectra from a set of unlabeled selenite experiments indicated that several of the
nucleotide hexoses decreased by ~50% relative to controls after 24 hours,
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13

Figure 2.16. Effect of selenite on C6-glucose derived enrichment of Ala in A549
13
A and B) A549 cells were pre-incubated for 2 hours with C6-glucose followed by treatment with
13
13
or without 6.25 µM Na2SeO3. Harvest hour denotes time after treatment. C2 (A) and C3 (B)-Ala
isotopologues were quantified via GC-MS from medium aliquots taken from the onset of
treatment (0 h) and at cell harvest. 0 h values were subtracted from harvest hour values and the
resulting quantity was normalized to total protein to calculate the amount of Ala produced. C and
D) Intracellular Ala measurements from the same experiment. Polar metabolites were extracted
and Ala was quantified via GC-MS and normalized to total protein.
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including UDP-GlcNAc (Fig. 2.17A). Selenite-induced reduction of these same
nucleotide hexoses was substantially less when the experiment was repeated in
NHBE cells (Fig. 2.17A). Quantitation yielded a ~2-fold decrease in selenitetreated A549 cells and a somewhat smaller decrease in NHBE cells (Fig. 2.17B
and C). Interestingly, UDP-GlcNAc was more substantially affected by selenite
treatment than UDP-GalNAc in both A549 and NHBE, suggesting some
specificity for UDP-GlcNAc synthesis. I then measured the time course of
enrichment of UDP-GlcNAc, UTP, and ATP in selenite-treated A549 cells using
both 13C6-glucose and 13C5,15N2-Gln tracers. UDP-GlcNAc is both analytically and
biologically interesting as its synthesis involves contributions from glycolysis,
pentose phosphate pathway, hexosamine biosynthetic pathway, Krebs’ cycle,
nucleotide biosynthesis, and glutaminolysis (Figs. 2.18A and B). By analyzing the
time course enrichment of UDP-GlcNAc from labeled precursors, one can make
conclusions about the flux through the pathways that contribute towards its
synthesis. When we measured UDP-GlcNAc isotopologues from selenite-treated
A549 cells with

13

C6-glucose tracer, I found that the time course of enrichment

was generally attenuated with respect to controls (Fig. 2.19).
13

13

C5 ,

13

C6, and

C13-UDP-GlcNAc enrichment was delayed in selenite-treated cells as shown in

figures 2.19B, C, and D. Furthermore, the enrichment of more fully labeled
isotopologues such as

13

C15-UDP-GlcNAc was immeasurable in selenite treated

A549 cells (Fig. 2.19E).
Presumably,

13

C5 and

13

C6-UDP-GlcNAc represent isotopologues having fully

labeled ribose and gluose moieties, respectively, due to their rapid accumulation
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C

Figure 2.17. Effect of selenite on nucleotide hexosamines
A) A549 and NHBE cells were treated with or without 6.25 µM Na2SeO3 for 24h. Polar
metabolites were extracted, and 1D proton spectra were recorded. Spectra were superimposed
and normalized to total protein to assess differences. UDP-GlcNAc peaks at 5.5 ppm were
quantified in A549 (B) and NHBE (C) using Mnova spectral analysis software and normalized to
total protein. *p<0.01; n=3
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Figure 2.18. Contributions from glucose and Gln in UDP-GlcNAc biosynthesis
13
A) Heavy carbon from C6-glucose is incorporated into UDP-GlcNAc at several points during its
13
13
13
synthesis. C2 or C3-Asp generated from the flow of C through glycolysis, PDH, Krebs’ cycle,
13
and transamination of labeled OAA is incorporated into the uracil ring. C5-ribose of the
13
nucleoside diphosphate is generated from glycolysis the pentose phosphate pathway. The C6glucose moiety of UDP-GlcNAc is generated during the first few steps of the HBP. Finally, the
13
13
15
13
15
C2-acetyl group is generated from glycolysis and PDH. B) C and N from C5, N2-Gln are
incorporated into UDP-GlcNAc at several points during its synthesis. CPS II can generate labeled
15
13
15
15
N3 uracil from C5, N2-Gln substrate. Uracil N1 is generated from transamination of either
13
15
13
fully labeled or unlabeled OAA with C5, N2-Gln. C4-6 of uracil can be generated through
13
15
glutaminolysis of C5, N2-Gln and subsequent transformation of fully labeled Glu and a-KG
13
13
15
through the TCA cycle to C4-OAA, which can then be transaminated from C5, N2-Gln to form
13
15
fully labeled Asp. C4, N1-Asp is then incorporated into the uracil ring during pyrimidine
synthesis. The amino group of glucosamine can be generated from the GFAT reaction of the HBP
13
15
using C5, N2-Gln as substrate. Finally, the acetyl group of N-acetylglucosamine can be
13
13
generated from C4-malate followed by malic enzyme mediated conversion to C-pyruvate and
13
C2-acetyl-CoA via PDH.
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Figure 2.19. Effect of selenite on UDP-GlcNAc enrichment from glucose
13
13
13
13
13
FT-MS quantified C0 (A), C5 (B), C6 (C), C13 (D), and C15 (E) UDP-GlcNAc isotopologues.
13
A549 cells were pre-incubated with C6-glucose for 2 hours and then treated with or without 6.25
µM Na2SeO3. Cells were harvested at 0, 1.5, 3, 6, 10, and 24 hours post treatment. Nucleotides
were extracted and UDP-GlcNAc was measured via FT-MS. Plots represent the intensity of the
designated isotopologue divided by the total intensity as a percentage.
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and depletion as more fully labeled species are generated. 13C13- and 13C15-UDPGlcNAc likely represent ribose plus glucose labeling and combinations of labeling
in the acetyl group and uracil ring. Taken together these enrichment patterns
indicate delayed enrichment of ribose and glucose with preferential blockage of
the uracil and/or acetyl subunits.
In order to more fully explore these enrichment patterns, the FT-MS data
were deconvoluted using the genetic algorithm for isotopologues in metabolic
systems or “GAIMS” developed by Dr. Hunter Moseley. This non-steady-state
modeling algorithm deconvolutes the UDP-GlcNAc isotopologue data into the
time course enrichment of its subunits: glucose, ribose, uracil, and the acetyl
group. When the algorithm was applied, the results indicated that the acetyl
group and uracil enrichment were preferentially delayed by selenite treatment as
illustrated in figures 2.20C, D, and E. However, ribose and glucose enrichment
were less substantially affected by selenite treatment, despite the increased
uptake rate of glucose (Figs. 2.20A and B). These findings are again consistent
with an increase in glycolytic flux and reallocation of glucose carbon into lactate
at the expense of pyrimidine synthesis as well as ribose synthesis via the PPP.
Interestingly, the flux of glucose carbon through the HBP appears to be mostly
intact with selenite treatment and preferentially blocked downstream of
glucosamine synthesis as suggested by the negligible effect on

13

C6-UDP-

GlcNAc accumulation.
When we examined the enrichment patterns in NHBE cells incubated with
13

C6-glucose tracer we found that selenite had no effect on UDP-GlcNAc
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Figure 2.20. GAIMS deconvolution of UDP-GlcNAc isotopologue distribution in A549
FT-MS data from figure 2.18 were deconvoluted as described. Individual plots represent the time
13
13
13
13
course enrichment of the C6-glucose (A), C5-ribose (B), C2-acetyl (C), and C1-3-uracil (D-F)
subunits of UDP-GlcNAc. Data are represented as the fraction of selenite treated subunit over the
total. Attention should be given to the y-axes as the scales vary widely among subunits.
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enrichment (Figs. 2.21A-D). We then measured the UDP-GlcNAc isotopologue
distribution generated from tumor and adjacent benign tissue slices treated with
selenite and incubated with

13

C6-glucose tracer for 24 hours. Enrichment of the

acetyl group and/or uracil ring appeared to be preferentially blocked in both the
tumor and benign tissue as evidenced by decreased amounts of

13

C13-UDP-

GlcNAc.
I then measured the UDP-GlcNAc isotopologue distribution generated
when A549 cells were incubated with
13

13

C5,15N2-Gln tracer. As expected,

C0,15N0-UDP-GlcNAc plateaued at a higher level in selenite-treated cells than in

controls (Fig. 2.22A). In order to assess the rate of depletion in treated cells, the
data were assumed to follow the simple exponential decay model:

!! =  < ! > +  (!! −  < ! >)!!"
As illustrated in table 2.2 the rate of

13

Eq. 2.1

C0,15N0-UDP-GlcNAc depletion in selenite-

treated cells was actually greater than in controls suggesting a possible
stimulation of UDP-GlcNAc synthesis or utilization initially, followed by an abrupt
decrease as nitrogen and carbon from Gln are blocked from entry into these
pathways.
Interestingly,

13

C0,15N1-UDP-GlcNAc accumulated in selenite treated cells

in contrast to controls, suggesting that at least one nitrogen-donating step in
UDP-GlcNAc synthesis was not inhibited by treatment (Fig. 2.22B).

13

C2,15N1-

UDP-GlcNAc also accumulated with selenite treatment as shown in figure 2.22C,
suggesting that malic enzyme decarboxylation of fully labeled malate to pyruvate
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Figure 2.21. Effect of selenite on UDP-GlcNAc enrichment from glucose in NHBE and
human tissue slices
13
NHBE cells were incubated with C6-glucose and treated with or without 6.25 µM Na2SeO3 for 24
13
13
13
13
hours. Nucleotides were extracted and C5 (A), C6 (B), C13 (C), and C15 (D) UDP-GlcNAc
isotopologues were measured via FT-MS. Plots represent the intensity of the designated
isotopologue divided by the total intensity as a percentage. E) Patient tissue slices were cultured
13
in C6-glucose supplemented medium and treated with or without 6.25 µM Na2SeO3 for 24 hours.
Nucleotides were extracted and UDP-GlcNAc isotopologue fractional distribution was measured
via FT-MS. The fractional enrichment of selenite-treated isotopologue was then divided by the
corresponding non-treated control value for each sample to obtain the fraction of control for each
isotopologue. Data were plotted as fraction of control averaged from three separate patients.
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Figure 2.22. Effect of selenite on UDP-GlcNAc enrichment from Gln in A549
13
15
A549 cells were pre-incubated for 2 hours with C5, N2-Gln and treated with or without 6.25 µM
Na2SeO3 for 24 hours. Cells were harvested at 0, 1.5, 3, 6, 10, and 24 hours post treatment.
Nucleotides were extracted and UDP-GlcNAc was measured via FT-MS. Plots represent the
intensity of the designated isotopologue divided by the total intensity as a percentage.

13

15

Table 2.2. Effect of selenite on exponential decay of C0, N0-UDP-GlcNAc in A549
13
15
-kt
C0, N0-UDP-GlcNAc FT-MS data were fit to the equation, yt= <y> + (y0 - <y>) , in order to
obtain the above variables. K values for the curves were significantly different with p values <
0.0001.
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and then acetyl-CoA was functioning as described earlier. However, this result is
puzzling given that flux through glutaminolysis and subsequently the TCA cycle is
clearly impeded with selenite treatment. Perhaps there is an initial brief
stimulation of glutaminolysis as suggested by table 2.2 followed by inhibition
which results in accumulation of

13

C2,15N1-UDP-GlcNAc as more fully labeled

isotopologues are blocked. More highly labeled isotopologues, including
13

C3,15N2,

13

C2,15N3,

13

C3,15N3, and

13

C5,15N3-UDP-GlcNAc,

were

greatly

attenuated by selenite, reinforcing that two out of the three nitrogen donating
steps were inhibited along with incorporation of fully labeled Asp from labeled
OAA transamination (Figs. 2.22D-F).
Surprisingly, when I measured UDP-GlcNAc isotopologues in NHBE cells
grown with

13

C5,15N2-Gln tracer nearly 100% were unlabeled, indicating little if

any de novo synthesis from Gln. Furthermore, there was no effect from selenite
on the distribution (Fig. 2.23A and B). As indicated in figure 2.17, UDP-GlcNAc
represents a substantial portion of the hexosamine nucleotide pool. Taken
together, these data suggest that de novo synthesis of UDP-GlcNAc in NHBE
cells incorporates carbon and nitrogen primarily from glucose and/or endogenous
Gln to maintain steady concentrations upon cell division. I then repeated these
measurements in the tissue slice model with

13

C5,15N2-Gln tracer from three

different patients. I found that selenite significantly reduced
and

13

13

C0,15N1,

13

C0,15N2,

C0,15N3-UDP-GlcNAc in tumor tissue compared with paired benign lung

tissue suggesting inhibition of the nitrogen donating steps in hexosamine
biosynthesis (Fig. 2.23C).
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Figure 2.23. Effect of selenite on UDP-GlcNAc enrichment from Gln human patient tissue
slices
13
15
A and B) NHBE cells were incubated with C5, N2-Gln and treated with or without 6.25 µM
Na2SeO3 for 24 hours. Nucleotides were extracted and UDP-GlcNAc was measured via FT-MS.
Plots represent the intensity of the designated isotopologue divided by the total intensity as a
percentage. C) UDP-GlcNAc isotopologue distribution from selenite-treated tumor and adjacent
benign tissue slices. Data represent the average from three separate patients depicted as fraction
of selenite over control. *p<0.05; n=3

	
  
62	
  

In order to discriminate labeling differences in UDP-GlcNAc between uracil
and the acetyl group caused by selenite, I then measured enrichment patterns in
UTP. UTP contains the uracil ring and ribose of UDP-GlcNAc without Nacetylglucosamine. Therefore, by studying tracer incorporation into UTP one can
make assumptions about which specific steps of UDP-GlcNAc synthesis were
inhibited by selenite treatment. When A549 cells were given

13

C6-glucose tracer,

unlabeled UTP plateaued at a higher level with selenite treatment, again
suggesting either decreased synthesis or utilization of UTP (Fig. 2.24A).
Analogous to table 2.2, the rate of
(Table 2.3).

13

13

C0-UTP was modeled using equation 2.1

C0-UTP decreased at the same rate for both controls and selenite-

treated cells, suggesting that selenite reduced the overall synthesis from glucose
and/or utilization of UTP, but not the initial rate. Selenite delayed
accumulation; however,

13

13

C5-UTP

C7-UTP was substantially more affected suggesting

preferential inhibition in Asp label incorporation (Figs. 2.24B and C). When the
experiment was repeated using

13

C5,15N2-Gln tracer, similar pathways appeared

to be affected. Specifically, labeled Asp incorporation into the uracil ring was
preferentially blocked by selenite treatment as evidenced by the depletion of
13

C3,15N1 and

13

C3,15N2-UTP (Figs. 2.24F and G). The predominant isotopologue

observed in the selenite-treated cells was fully unlabeled UTP (Fig. 2.24D), and
all others were either absent or depleted for the duration of the experiment,
suggesting that transamination of fructose-6-phosphate to glucosamine-6phosphate during hexosamine biosynthesis is not as affected by selenite
treatment as the other nitrogen-incorporating steps. When I measured UTP
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Figure 2.24. Effect of selenite on UTP enrichment from glucose and Gln in A549
13
A-C) A549 cells were pre-incubated for 2 hours with C6-glucose and treated with or without 6.25
13
15
µM Na2SeO3 for 24 hours. D-G) A549 cells were pre-incubated for 2 hours with C5, N2-Gln and
treated with or without 6.25 µM Na2SeO3 for 24 hours. Cells were harvested at 0, 1.5, 3, 6, 10,
and 24 hours post treatment. Nucleotides were extracted and UTP was measured via FT-MS.
Plots represent the intensity of the designated isotopologue divided by the total intensity as a
percentage.

13

Table 2.3. Effect of selenite on exponential decay of C0-UTP in A549
13
-kt
C0-UTP FT-MS data were fit to the equation, yt= <y> + (y0 - <y>) , in order to obtain the above
variables. K values for the curves were statistically the same.
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isotopologues from both tracers in treated NHBE cells, no differences between
treatments were noted. Again, I observed very little incorporation of Gln label
(Fig. 2.25). Interestingly, the treated tissue slices recapitulated the selenite
effects on tumor tissue, specifically with regards to Asp incorporation into the
uracil ring (Fig. 2.26).
Finally, I measured the isotopologue distributions in ATP as a
representation of purine metabolism using the experiments detailed above (Fig
2.27). Similar to UDP-GlcNAc and UTP, unlabeled ATP plateaued at a higher
level in selenite-treated A549 cells as shown in figure 2.27A, suggesting
decreased synthesis or utilization. The rates of both 13C0-ATP depletion and 13C5ATP accumulation were modeled using equation 2.1 and the following model:

! = !! +< ! > (1 − ! !!" )

Eq. 2.2

As shown in table 2.4, the depletion rate of unlabeled ATP was the same for both
treated and untreated A549; however, the rate of 13C5-ATP was significantly
reduced in selenite-treated cells. These data are consistent with an overall
decrease in the synthesis from glucose and/or utilization of ATP with selenite
treatment.
Consistent with the parameters determined in table 2.4, labeling of the
ribose subunit was slightly delayed, while enrichment of the adenine ring was
significantly slower as evidenced by figures 2.27B and C. Carbon in the adenine
ring is derived from Gly, N10-formyl-THF, and CO2. Interestingly, 13C1-Gly
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Figure 2.25. Effect of selenite on UTP enrichment from glucose and Gln in NHBE
13
13
15
NHBE cells were incubated with either C6-glucose (A-C) or C5, N2-Gln (D and E) and treated
with or without 6.25 µM Na2SeO3 for 24 hours. Nucleotides were extracted and UTP was
measured via FT-MS. Plots represent the intensity of the designated isotopologue divided by the
total intensity as a percentage.
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Figure 2.26. Effect of selenite on UTP enrichment from glucose and Gln in human patient
tissue slices
13
13
15
Tumor and adjacent benign tissue slices were incubated with C6-glucose (A) or C5, N2-Gln
(B) tracers and treated with or without 6.25 µM Na2SeO3 for 24 h. Nucleotides were extracted and
UTP was measured via FT-MS. Data represent the average from three separate patients
depicted as fraction of selenite over control. *p<0.05; n=3
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Figure 2.27. Effect of selenite on ATP enrichment from glucose and gln in A549
13
A-C) A549 cells were pre-incubated for 2 hours with C6-glucose and treated with or without 6.25
13
15
µM Na2SeO3 for 24 hours. D-H) A549 cells were pre-incubated for 2 hours with C5, N2-Gln and
treated with or without 6.25 µM Na2SeO3 for 24 hours. Cells were harvested at 0, 1.5, 3, 6, 10,
and 24 hours post treatment. Nucleotides were extracted and ATP was measured via FT-MS
Plots represent the intensity of the designated isotopologue divided by the total intensity as a
percentage.
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13

13

Table 2.4. Effect of selenite on exponential decay of C0-ATP and accumulation of C5-ATP
in A549
13
13
-kt
C0 and C5-ATP FT-MS data were fit to the equations, yt= <y> + (y0 - <y>) and y = y0 + <y>(1
-kt
13
– e ), respectively, in order to obtain the above variables. K values for the rate of C0-ATP
13
depletion were statistically the same, but were significantly different for C5-ATP accumulation
with p values < 0.05.
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appeared to accumulate before 13C2-Gly in A549 control cells incubated with
13

C6-glucose tracer, and enrichment was delayed by selenite treatment; however,

the validity of these data were compromised due to noise (Fig. 2.28). Since the
entire Gly backbone is incorporated into the adenine ring, one would expect to
find 13C1 followed by 13C2 labeling in the adenine ring based upon the Gly
enrichment pattern. This is likely why 13C1-adenine accumulates in A549 cells,
since 13C6-ATP is presumably 13C5-ribose plus 13C1-adenine as 13Cribose-ATP is
clearly and independently measurable from the NMR spectra shown in figure 2.4.
However, 13C could also be contributed from N10-formyl-THF, which can itself be
synthesized in part from Gly or Ser, so it is difficult to determine precisely where
the adenine label is derived from.
Four out of the five nitrogen atoms in ATP can be traced back to Gln as
their source, either directly or from Asp transamination as supported by a
predominance of

13

C0,15N4-ATP seen in the

13

C5,15N2-Gln labeled controls of

figure 2.27H. The predominant isotopologue observed for selenite-treated cells
from this experiment was unlabeled ATP, again suggesting decreased purine
synthesis and/or utilization (Fig. 2.27D). Interestingly,

13

C0,15N1-ATP also

accumulated in selenite treated A549 cells; however, due to the similarity of
nitrogen donating steps during purine synthesis, it is likely a combination of

15

N1 -

adenine isotopomers (Fig. 27E). Analysis of the isotopologue distribution in

13

C6 -

glucose and

13

C5,15N2-Gln labeled NHBE cells again yielded little if any changes

induced by selenite treatment (Fig. 2.29). Interestingly, ATP also incorporated
very little carbon or nitrogen from Gln over 24 h as evidenced by the
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Figure 2.28. Effect of selenite on Gly enrichment from glucose in A549
13
A549 cells were pre-incubated for 2 hours with C6-glucose and treated with or without 6.25 µM
Na2SeO3 for 24 hours. Cells were harvested at 0, 1.5, 3, 6, 10, and 24 hours post treatment. Polar
metabolites were extracted and Gly was measured via GC-MS and normalized to total protein.
Plots represent the intensity of the designated isotopologue divided by the total intensity as a
percentage.
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Figure 2.29. Effect of selenite on ATP enrichment from glucose and Gln in NHBE
13
13
15
NHBE cells were incubated with either C6-glucose (A-C) or C5, N2-Gln (D) and treated with or
without 6.25 µM Na2SeO3 for 24 hours. Nucleotides were extracted and ATP was measured via
FT-MS. Plots represent the intensity of the designated isotopologue divided by the total intensity
as a percentage.
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Fig. 2.30. Effect of selenite on ATP enrichment from glucose and Gln in human patient
tissue slices
13
13
15
Tumor and adjacent benign tissue slices were incubated with C6-glucose (A) or C5, N2-Gln
(B) tracers and treated with or without 6.25 µM Na2SeO3 for 24 h. Nucleotides were extracted and
ATP was measured via FT-MS. Data represent the average from three separate patients depicted
as fraction of selenite over control. *p<0.05; n=3
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predominance of unlabeled ATP with

13

C5,15N2-Gln tracers (Fig. 2.29D). Finally,

when we applied fully labeled glucose tracer to the tissue slices, we found that
selenite had little effect on enrichment of ribose (Fig. 2.30A). Nitrogen
incorporation from

13

C5,15N2-Gln tracer into the adenine ring of ATP was

significantly reduced with selenite treatment in the cancer tissues; however,
benign tissues were also significantly affected as illustrated in figure 2.30B, and
actually more so for 13C0,15N2-ATP.
2.3.6 Selenite decreases UDP-GlcNAc utilization
As discussed previously, UDP-GlcNAc decreased in selenite treated A549
cells substantially more so than in NHBE cells (Fig. 2.17). In order to determine if
this decrease in UDP-GlcNAc was matched by a decrease in its utilization for
protein modification, I examined the levels of O-GlcNAc glycosylation in selenite
treated A549 cells. Interestingly, selenite induced a global reduction in O-GlcNAc
modification as shown in figure 2.31. Glycosylation was also measured in NHBE
cells and was less than in untreated A549 cells, analogous to the difference
between tumor and benign tissue reported in the literature [45]. Furthermore,
selenite did not have any effect on O-GlcNAc glycosylation in NHBE. I then
attempted to isolate several putative targets of O-GlcNAc modification including
the proto-oncogene protein c-MYC and mitochondrial transporter VDAC, both of
which have been established as targets of OGT. Selenite has a significant effect
on glutaminolysis and TCA cycle activity (see above); therefore, I chose to focus
on c-MYC and VDAC due to their roles in Gln and mitochondrial metabolism,
respectively [53, 68-70]. However, after immunoprecipitation, neither protein
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Figure 2.31. Effect of selenite on UDP-GlcNAc utliization
A549 cells were treated with or without 6.25 µM Na2SeO3 for 24 hours and total protein was
extracted. Lysates from treated A549 and untreated NHBE cells were probed for o-GlcNAc
modification via WB. α-tubulin was also probed as loading control.
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appeared to be modified by UDP-GlcNAc. We have since begun to focus on a
proteomics approach combined with immunoprecipitation; this investigation is
ongoing.

2.4 Conclusions
By utilizing tracer-based experimental design, this study was able to
expand upon previous work by Fan et al. [60] on selenite-induced disruption of
cancer cell metabolism. NSCLC tissue slices were demonstrated to be
metabolically viable due to their uptake and incorporation of labeled tracers into
metabolic intermediates. Furthermore, selenite induced massive necrosis in
cancer tissue that was unmatched in the adjacent benign tissue, thereby
illustrating its potency as an anti-cancer agent for this model. In order to expand
upon these findings, I then pursued a thorough metabolic profile of seleniteperturbed metabolism by contrasting A549 human lung cancer cells with
immortalized NHBE cells and NSCLC lung tissue.
During this investigation, I studied numerous selenite-induced
disturbances in A549 metabolism. The driving force behind many of these effects
seems to be a dramatic attenuation of glutaminolysis induced by selenite. Gln is
one of the major anapleurotic substrates of the TCA cycle, and it contributes both
carbon and nitrogen for the biosynthesis of amino acids, nucleotides, and Krebs’
cycle intermediates to facilitate aerobic respiration. When A549 cells were
labeled with 13C6-glucose, I found a dramatic reduction in the enrichment of
doubly labeled TCA cycle intermediates citrate, fumarate, and malate along with
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doubly labeled Asp suggestive of decreased entry of glucose into the cycle.
Furthermore, when 13C5,15N2-Gln tracer was applied, I found a severe depletion
and accumulation of labeled Glu and Gln, indicating impaired glutaminolysis.
Together, this indicates a decrease in flux through the TCA cycle that would
presumably lead to an impaired ability to generate NADH and FADH2 for
oxidative phosphorylation, as well as provide intermediates for anabolic
metabolism. As evidenced by the increase in 13C3-lacate and 13C3-Ser with
selenite treatment, glycolytic flux is likely accelerated in order to augment the
high cancer cell energy requirements through substrate level phosphorylation.
Interestingly, I found that this effect on TCA flux was not reproduced in NHBE
cells, suggesting that these effects are somehow cancer specific. Furthermore,
selenite-induced Krebs’ cycle flux attenuation was recapitulated in the tissue slice
experiments, reinforcing this hypothesis within the actual tumor
microenvironment.
I then examined labeling patterns in UDP-GlcNAc, UTP, and ATP from
13

C6-glucose and 13C5,15N2-Gln to determine if these disturbances in TCA cycle

flux and anapleurosis were propagated into nucleotide synthesis. Through the
analysis of 13C6-glucose labeled UDP-GlcNAc and subsequent GAIMS
deconvolution, I showed that uracil and acetyl group enrichment were
preferentially delayed by selenite treatment. Uracil synthesis requires
incorporation of Asp into its ring, which itself is a product of Krebs’ cycle
intermediate OAA’s transamination. Given that selenite reduces anapleurosis of
the TCA cycle, it follows that Asp synthesis would also be reduced as well as its
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incorporation into the uracil ring. In addition, uracil biosynthesis requires the
activity of the mitochondrial enzyme dihydroorotate dehydrogenase, which
requires reoxidation of the flavin by ubiquinone (cf complex II) and thus a
functional respiratory chain [71]. Furthermore, selenite-induced stimulation of
glycolysis and subsequent lactic acid fermentation to replenish NAD+ could
reduce flux through pyruvate dehydrogenase, limiting the acetyl-CoA substrate
available for acetylation of glucosamine-6-phosphate during the glucosamine-6phosphate N-acetyltransferase reaction. These blocked steps in hexosamine
synthesis resulted in a significant reduction of total UDP-GlcNAc in A549 cells.
Examination of 13C5,15N2-Gln incorporation into UDP-GlcNAc and UTP
reiterated these findings, illustrating that uracil synthesis from Asp was impaired
by selenite. GFAT catalyzed transamination of fructose-6-phosphate to
glucosamine-6-phosphate appeared to be the only nitrogen-donating reaction of
UDP-GlcNAc synthesis that was not inhibited by selenite treatment, likely due to
the increased pool of Gln available due to diminished glutaminolysis. When I
repeated the experiments in NHBE cells, I found no effect from selenite on
nucleotide synthesis. Furthermore, NHBE cells did not utilize exogenous Gln for
nucleotide synthesis, reinforcing that Gln is a preferential nutrient of transformed
cancer cells. Here again, analysis of tissue slice nucleotide synthesis from
labeled precursors recapitulated the findings from the cell-based experiments
illustrating a selenite-induced reduction in biosynthesis. Benign tissues were,
however, affected as well by selenite treatment suggesting some effect on
nucleotide synthesis in the surrounding lung tissue. Differences in the response
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to selenite between tumor and adjacent benign tissue are likely to be smaller
than in cell monoculture. The presence of stromal cells, in both the tumor and
benign tissue along with inflammation, is partially responsible for reducing these
differences.
Finally, I found that the reduction in UDP-GlcNAc biosynthesis caused by
selenite was followed by a global reduction in its glycosylation of protein targets
by OGT. Given the increasing recognition of the importance of O-GlcNAcylation
in protein regulation[49-51], these selenite-induced downstream effects could
have compounding implications for tumor cell survival and proliferation. However,
further work is needed in order to determine which potential targets may be
mediating these effects.
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CHAPTER 3-SELENITE INHIBITS GLUTAMINOLYSIS BY
DECREASING THE EXPRESSION OF GAC
3.1 Introduction
Selenium is a micronutrient that is incorporated into the 21st protein coding
amino acid, selenocysteine [10]. It functions primarily as an anti-oxidant via its
catalytic role in redox enzymes like thioredoxin reductase and glutathione
peroxidase [72]. A selenium deficient diet leads to a constellation of syndromes
including bone deformities, thyroid disorders, weakened immune response, and
an endemic cardiomyopathy of the Keshan province in China [13-15]. Selenium
also has a well-established history of anti-cancer and chemopreventive activity
including its investigation in several large-scale human drug trials [20, 26, 27].
The anti-cancer or chemopreventive potential of selenium is highly dependent on
the chemical species that is used, and a wide variety of organic and inorganic
compounds have been studied. The discrepancy in efficacy of varying selenocompounds may have been responsible for the failure of the SELECT trial (which
used pure selenomethionone and vitamin E, and thus further research into
selenium toxicity is needed [27].
Selenite (SeO32-) is one of the main inorganic forms of selenium that has
shown promise as a chemopreventive and chemotherapeutic. Selenite has been
shown to induce dose-dependent apoptosis in a variety of cancer types including
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lung, prostate, glioma, and colorectal cancers [17, 24, 73, 74]. Recently, Park et
al. uncovered evidence of ROS-mediated autophagy in A549 lung cancer cells
eventually leading to cell death [22]. However, despite these findings, the exact
mechanism of selenite-induced toxicity in cancer cells remains unclear. One of
the main mechanistic theories involves the generation of ROS such as
superoxide, hydrogen peroxide, and/or hydroxyl radical from the successive
reduction of SeO32- to elemental selenium (Se0) [25]. The ROS generated can
then induce DNA and protein damage that precipitates a cascade of events
eventually leading to apoptosis and cell death. ROS accumulation and cell death
are blocked in selenite-treated A549 cells by supplementation with Nacetylcysteine (NAC), a commonly used antioxidant, which supports this
mechanistic theory [22].
Previously, using tracer-based experimental design Fan et al. showed that
selenite treatment of A549 cells induces numerous metabolic alterations
including disruption of the TCA cycle, glutaminolysis, and glycolysis [60]. The
utility of stable isotope resolved metabolomics (SIRM) has also been
demonstrated in establishing the differences between metabolic phenotypes of
cancer and benign human lung tissues, the profiling of lipid biosynthesis in breast
and lung cancer, and the non-steady state modeling of the hexosamine
biosynthetic pathway in prostate [33, 55, 56]. Here, I employed SIRM as an
approach towards mechanistic understanding of selenite toxicity in human lung
cancer models, specifically disrupted glutamine (Gln) metabolism.
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Gln is one of the main anapleurotic substrates of the TCA cycle and
contributes in the synthesis of nucleotides, amino acids, hexosamines, and
glutathione among other metabolites. Gln consumption is often increased in
tumors and glutaminase (GLS) inhibition has been shown to induce apoptosis in
kidney and lung cancer cells overexpressing MYC, the proto-oncogene that
drives GLS expression [39]. We have also found that c-MYC expression is
elevated in the majority of NSCLC tumors relative to adjacent benign tissue in
our ongoing patient study. Since our previous findings indicated selenite
disrupted Gln metabolism in A549 cells and the large body of literature
surrounding Gln’s importance in tumor nutrition, I have focused on Gln
metabolism as a possible source of toxicity in A549 cells [23].
GLS exists as two main isoforms in mammals, GLS1 and GLS2 [75].
GLS2 or liver type GLS (LGA) is partially regulated through interaction with Tax
interacting protein (TIP-1) via its C-terminal domain and has been implicated as a
tumor supressor [76, 77]. However, differences in the C-terminal domain of GLS1
prohibit interaction with TIP-1 [78]. GLS1 can be subdivided into two splice
variants, kidney type GLS (KGA) and GLS C (GAC). GAC is a splice variant of
KGA that has been shown to be upregulated at the mRNA level in a variety of
cancers including those of brain, colorectal, and breast [79-82]. GAC was
recently shown to be localized exclusively in the mitochondria and is activated by
inorganic phosphate [83]. GAC expression is regulated at least in part via c-MYC
and interestingly has also been shown to be a target of mitochondrial Lon
protease mediated degradation when modulated by diphenylarsenic acid [84,
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85]. These recent findings along with this study suggest an increasingly important
role for GAC in tumor metabolism and selenite mediated anti-cancer activity.

3.2 Methods
Cell culture: A549 cells were grown in glucose-free, glutamine-free DMEM
medium supplemented with 10% FBS, 0.2% glucose, 4 mM glutamine, and 100
I.U./mL penicillin 100 µg/mLstreptomycin at 37 °C and 5% CO2. Na2SeO3
solutions were prepared immediately prior to use and sterilized using 0.22 µm
syringe filter. Cells were grown to 70% confluence for all experiments. Two hours
prior to treatment, medium was aspirated and replaced with half volume of the
tracer medium. The remaining medium was then added with doubled Na2SeO3
concentration in order for cells to be conditioned with the tracer medium prior to
treatment.

Tissue slices: During NSCLC surgical resection, very thin slices (0.5-1 mm) were
prepared from tumor and adjacent benign tissue by the operating surgeon (Dr. M.
Bousamra II). Tissue slices were immediately placed in T-25 culture flasks with 8
mL DMEM medium supplemented with 10% FBS, 100 I.U./mL penicillin 100
µg/mLstreptomycin, 0.2% glucose, and 4 mM Gln. Either
13

13

C6-glucose or

C515N2-Gln was used for tracer experiments. Slice medium was then treated

with or without 6.25 µM Na2SeO3. Flasks were then placed on a rotator in a cell
culture incubator at 37 °C and 5% CO2 for 24 h. After 24 h, medium was collected
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for downstream analysis, and tissue slices were washed with PBS before flash
freezing in LN2.

Extraction of metabolites: At the time of harvest, medium was collected before all
plates were washed three times with ice cold PBS, and PBS was removed as
much as possible by aspiration. The cells’ metabolism was then quenched with 1
ml of CH3CN kept at -20°C before 0.75 ml of nanopure water was added and
cells were harvested by scraping. The process was repeated once before CHCl3
addition to a final CH3CN:H2O:CHCl3 ratio of 2:1.5:1 to obtain the polar, nonpolar and insoluble proteinaceous interface fractions for downstream analysis
[65, 66]. For extraction of metabolites from human tissue slices, frozen tissue
was first pulverized to powder in a liquid nitrogen freezer mill. The frozen powder
was then extracted using the same ratio of CH3CN:H2O:CHCl3 detailed above.

Glutaminase assays: For assaying whole cell glutaminase activity, cells were
washed with PBS, trypsinized, and flash frozen in lN2. Cell pellets were
resuspended in and then sheared via aspiration through a 28.5 gauge syringe.
The assay solution consisted of cell lysate, 5 mM alpha-ketoglutarate, 200 mM
KH2HPO4, 0.2 mM EDTA, 48 U/mL glutamate dehydrogenase (GDH), 0.3 mM
NADH, and 20 mM Gln. The reaction was initiated with Gln and the absorbance
was measured continuously at 340 nm for 20 min. Specific activity was then
calculated from the change in the amount of NADH produced (derived from A340
and molar absorptivity) over time. For mitochondrial activity assays, mitochondria
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preparations described below were used. The assay solution consisted of 0.2
mM Tris acetate pH 8.6, 20mM K2HPO4, 2mM NAD+, 15U/mL GDH, and 50mM
Gln, Reaction was initiated with Gln and 5 µg total protein was used per reaction.
Absorbance was then measured, and specific activity calculated as above.

Mitochondrial isolation: Cells were washed with PBS, trypsinized, and pelleted
before resuspending in 200 mM mannitol, 70 mM sucrose, 1 mM EGTA, 10 mM
HEPES pH 7.5. A protease and phosphatase inhibitor cocktail was added
immediately prior to isolation as follows: HALT protease inhibitor cocktail (Pierce
Biotechnology), 1 mM phenylmethylsulfonyl fluoride, 1 mM benzamidine, 2 mM
imidazole, and 1.15 mM Na molybdate. Cells were homogenized with 28.5 g
needles and then centrifuged at 1000 g for 10min. Supernatant was collected
and spun at 10,000-15,000 g for 15 min. Pellet was washed with 1 mL isolation
buffer, centrifuged at 15,000 g for 15 min, and suspended in 25 mM HEPES, 150
mM NaCl, 1 mM EDTA, and 0.01% triton X-100.

NMR experiments: All NMR experiments were conducted on a Varian Inova 14.1
T instrument equipped with 5 mm HCN cold probe. Cell extracts were dissolved
in D2O with 30 nmol d6-DSS, respectively, as internal standard. Shigemi tubes
were used for polar extracts to minimize sample volume and thus to concentrate
the metabolites. 1D proton spectra were recorded with an acquisition time of 2
seconds after initial presaturation of the H2O signal with a recycle time of 5
seconds. 1D

13

C-filtered HSQC spectra were measured using an acquisition time
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of 150 ms. 1D proton spectra were processed using a 1 Hz exponential line
broadening function and a zero fill of 128 k points. 1D

13

C-filtered HSQC spectra

were processed with a 6 Hz line-broadening exponential and 0.07 Hz Gaussian
functions and zero filled to 16 k points. Both types of spectra were processed
manually for baseline and phase corrections. 1D proton spectra were referenced
using the methyl signal of D6-DSS at 0 ppm, and 1D

13

C-filtered HSQC spectra

were referenced to the C4-Gln peak at 2.43 ppm. Metabolites were identified in
reference to an in-house standard database and quantified by calibration with the
methyl resonance of the DSS internal standard using the MestReNova NMR
processing software (Mestrelab Research, Santiago de Compostela, Spain) [59].

GC-MS analysis: An aliquot of the lyophilized extracts was derivatized in 50% Ntert-Butyldimethylsilyl-N-methyltrifluoroacetamide

with

1%

tert-

Butyldimethylchlorosilane (MTBSTFA + 1% TBDMSCl) in CH3CN before GC-MS
analysis. All GC-MS data were acquired on a ThermoFinnigan PolarisQ GC-Ion
trap MSn instrument (ThermoScientific, Rockford IL). One µL of the derivatized
sample was separated on a SGE Forte (Victoria, Australia) 5% phenyl capillary
column with the following dimensions: 50 m x 0.15 mm; 0.25 µm film thickness.
The GC parameters were as follows: injector and transfer line, 280 °C; oven, 60
°C for 2 min, 60 to 150 °C at 20 °C/min ramp, 150 to 300 °C at 6 °C/min ramp;
He carrier gas with flow rate of 1.5 mL/min. Spectra were acquired in segscan
mode with ranges of 140-206, 209-280, and 283-650 m/z with an acquisition time
of 0.97 s. Spectra were processed using Xcalibur MS software and quantified
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using a mixture of 63 standards at 50 µM each except for glutamate at 500 µM.
All samples and standards were spiked with 1 µM norleucine as internal
standard.

Western Blot: At time of harvest cells were lysed directly on the plate using 62.5
mM Tris, 2% SDS buffer at pH 6.8 before harvest by scraping, and protein
concentration was measured via the BCA method (Pierce). All protein extracts
were diluted in 4X loading buffer (50% glycerol, 4% SDS, 150 mM Tris pH 6.8, 1
mM DTT, 0.02% bromophenol blue, 10% β-mercaptoethanol) to 1X strength and
then boiled for 10 minutes prior to electrophoresis. Approximately 30 µg protein
was loaded for each sample onto a denaturing SDS 10 % acrylamide gel with a
6% stacking gel. Protein extracts were stacked for 30 min at 100 V and then
resolved for 1.5 h at 200 V using commercially available Tris/Gly/SDS buffer
(National Diagnostics, Atlanta, GA). Proteins were then transferred onto a PVDF
membrane (Immobilon-P, Millipore, Bedford, MA) at 25 V for 2 h at room
temperature in an Invitrogen transfer apparatus. All primary antibodies were
incubated with membrane at 4 °C on a rocker overnight as follows: KGA (cterminus specific, Abnova), 1:2000 in PBST with 5% non-fat powdered milk; GAC
(generously donated from Dias) 1:3300 in PBST; α-tubulin (Epitomics), 1:50,000
in PBST with 5% non-fat powdered milk. Membranes were then washed 3 times
with PBST before incubating 1 hour at room temperature with an HRPconjugated secondary antibody (Pierce, 1:2000 in PBST with 5% non-fat
powdered milk). Blots were then incubated in Pierce supersignal extended
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duration chemiluminescent reagent before exposure to x-ray film (SCBT) for
visualization. Expression was then quantified using ImageJ software.

RT-qPCR: At time of harvest, total RNA was extracted from cells using Trizol
reagent (Invitrogen) and protocol. RNA concentration and quality were
determined via absorbance on a Nanodrop instrument (Thermo Fisher), and
integrity was verified via agarose gel electrophoresis. cDNA was synthesized
using Invitrogen Superscript VILO cDNA synthesis kit. Primers for GAC and KGA
were designed and purchased through IDT and β-actin through Qiagen. SYBR
Green qPCR mastermix was purchased through Applied Biosystems. Primer and
template concentrations were optimized for amplification efficiencies >90%
before continuing with experimental assays. For quantification the ΔΔCt method
was applied with β-actin as the housekeeping gene.

Microscopy: A549 cells were grown to ~70% confluence in 6-well plates
containing sterilized cover slips before treating with 6.25 mM Na2SeO3. At 3, 6,
24 and 48 hours medium was aspirated. For ROS measurement 10 mM H2DCFDA (Molecular Probes) in 1 mL fresh medium was added to each well and
incubated at room temperature for 20 min. Medium was then replaced with 3 mL
fresh medium and cells were incubated for another 30 min at room temperature
to allow dye to hydrolyze. Cover slips were then washed with fresh medium, and
slides were placed face down onto slides pre-loaded with 20 mL PBS. Cover slip
edges were then sealed with fingernail polish. For mitochondrial staining 25-100
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nM MitoTracker Red (Molecular Probes) in 1 mL fresh medium was added to
each well and incubated at 37 °C for 0.5-1 hour. Coverslips were then washed
with fresh medium before placing on slide and sealing as above. Images were
recorded on an Olympus BX51 fluorescence microscope using a 100x /1.3 Ph3,
oil immersion lens (Olympus, Melville, NY) and appropriate filters (Omega
Optical, Brattleboro, VT).

Proliferation assays: Proliferation was measured in A549 according to the
protocol by Raspotnig et al. [64]. Briefly, at the time of measurement cell medium
was aspirated and replaced with minimal volume of 50% ethanol in H2O for 30
min. Ethanol was then aspirated and replaced with minimal volume of 0.2%
Janus green dye in PBS for 5 min. Dye was aspirated and plates were rinsed in
RO H2O and then air-dried. Dye was then dissolved in 0.5 N HCl and absorbance
was measured at 595 nm. 6.25 µM Na2SeO3 and 5mM Glu was used for all
proliferation assays. For rescue experiments, Glu and/or selenite were
introduced to media simultaneously and growth was quantified as the fraction of
absorbance over day 0.

Statistics: All metabolite amounts were normalized to total protein measured via
the BCA method. All error bars represent the standard deviation of an average of
experiments (the specific number of experiments is provided in appropriate figure
legends). For statistical significance of experiments where only a single variable
was measured (i.e., enzyme activity assay) the two-tailed Student paired t-test
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was used to calculate p values, and p values <0.05 were considered significant.
For experiments involving multiple measurements (i.e., measurement of
metabolites from NMR and MS analysis) the false discovery rate method
described by Benjamini and Hochberg was applied [67]. Briefly, naïve p-values
for all measured metabolites were calculated. These values were then ranked in
order of decreasing significance and assigned a rank number. A qi value was
then calculated according to the equation qi=kpi/i where i=rank of the p value
among the k tests. The false discovery rate (FDR) was then defined for every qi
value such that FDRi=min(qi,…,qk). Tests with p values <0.05 and an FDR value
<0.05 were then accepted as significant. For cell-based experiments, only Glu,
Gln, GSG, and GSH were measured for statistical differences among treatments.
For tissue experiments Glu, fumarate, malate, and Asp were measured.

3.3 Results and Discussion
3.3.1 Selenite disrupts Gln utilization in human lung cancer models
3.3.1.1 Cell culture
In order to probe SeO32- perturbed metabolism in cancerous and noncancerous lung models, A549 human lung cancer cells and non-transformed
NHBE cells were treated with or without 6.25 µM Na2SeO3, and metabolites in
polar extracts were measured using NMR and MS. An immediately obvious
feature of the polar metabolic profiles from SeO32- treated A549 cells was the
buildup and depletion of Gln and Glu, respectively, as illustrated in figure 3.1.
Quantitatively, Gln was elevated ~2.5-fold and Glu decreased ~3-fold (Fig. 3.2A).
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Figure 3.1. Effect of selenite on Gln metabolism.
1D proton spectra were recorded of polar extracts of A549 and NHBE cells treated for 24 hours
with 6.25 µM Na2SeO3. Spectra were superimposed and normalized to total protein to assess
differences between treatments. Selected region displays the C4 protons from both Gln and Glu.

Figure 3.2. Gln and Glu quantification from selenite treated A549 cells.
A) 1D proton spectra were recorded from the polar extracts of A549 cells treated with 6.25 µM
Na2SeO3 for 24 hours. C4-Glu and Gln proton peaks at 2.34 and 2.44 ppm were quantified and
normalized to total protein. *p<0.001; n=3. B) Total Gln and Glu normalized to total protein were
measured from GC-MS spectra of polar extracts recorded at 0, 1.5, 3, 6, and 24 hours of selenite
treatment.
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However, little to no effect on Gln or Glu was apparent in the corresponding
spectra of NHBE cells treated with the same concentration of SeO32- (Fig. 3.1).
Time course GC-MS measurements taken from SeO32- treated A549 cells
indicated that Gln and Glu levels began to increase and decrease, respectively,
at ~3 h of treatment and these changes continued for the duration of the
experiment (Fig. 3.2B). By ~6 h of selenite treatment, Glu depletion had
plateaued with a half-life of ~2 h, while Gln continued to accumulate suggesting
inhibition of the glutaminase reaction that converts Gln to Glu while maintaining
Gln import.
In order to further probe altered glutaminolysis in cell experiments,
13

C515N2-Gln was utilized as a tracer in time course experiments to directly

measure the conversion of Gln to Glu and downstream metabolites. 1D

13

C-

filtered HSQC spectra were recorded of the polar extracts of SeO32- treated
13

A549 cells to follow the time course changes in

C-labeled metabolites.

Consistent with findings from the unlabeled experiments, the selenite-induced
13

C-Gln buildup/Glu depletion began at ~3 h and the same trend continued

thereafter (Fig. 3.3). Selenite also elicited a depletion of
beginning at ~6 h of the treatment and a depletion of

13

13

C-labeled glutathione

C-labeled Asp and citrate

beginning at ~3 h of treatment, as illustrated in figure 3.3. Furthermore, the level
of downstream products of
i.e.

13

C5,15N1-Glu,

13

13

C5,15N2-Gln via glutaminase and the Krebs cycle,

C4-fumarate,

13

C4-malate, and

13

C4,15N1-Asp showed a

progressive decrease with selenite treatment, which began at ~3h to near nondetectable by 24h (Fig. 3.4). The corresponding metabolites in the controls
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Figure 3.3. Time course effect of selenite on Gln, Glu, and glutathione
1
1D H[33] HSQC spectra were recorded from polar extracts of A549 cells pre-incubated for 2
13
15
hours with C5, N2-Gln tracer and treated with or without 6.25 µM Na2SeO3 for 0, 1.5, 3, 6, 11,
and 24 hours. Control and selenite spectra were superimposed and normalized to total protein to
13
13
13
visualize differences between treatments in C-4-glutathione, C-4-Gln, and C-4-Glu at 2.54,
2.44, and 2.34 ppm, respectively.
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Figure 3.4. Time course quantitation of selenite effects on Gln-derived metabolites in A549
13
15
GC-MS spectra were recorded from A549 cells treated pre-incubated for 2 hours with C5, N2Gln tracer and treated with or without 6.25 µM Na2SeO3 for 0, 1.5, 3, 6, 11, and 24 hours.
13
15
13
13
13
15
C5, N1-Glu, C4-malate, C4-fumarate, and C4, N1-Asp were quantified and normalized to
total protein.
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continued to increase for the duration of the experiment, possibly because the
TCA cycle had not yet reached isotopic steady state. Fluctuations at 2 h may be
due to equilibration of metabolism to medium change.
3.3.1.2 Human Tissue Slices
Thin (0.5-1 mm) slices of tumor and adjacent benign lung tissue from
human non-small cell lung cancer (NSLSC) surgical patients were used as an
individualized model for human lung cancer. These tissue slices are analogous to
those described by Warburg, but are placed in medium rather than on wet
blotting paper, thereby giving much greater control over nutrient supply and
removal of waste products [29]. Such slices represent better models than
cultured cells as they contain much of the in situ microenvironment that is lost
with cell cultures. Including the orginal tissue architecture and the stromal cells of
the tumor. These tissue slices were treated with or without 6.25 µM Na2SeO3 in
the presence of

13

C5,15N2-Gln for 24 h. As shown in the 1D

spectra of figure 3.5A, the

13

13

C-filtered HSQC

C-labeled Gln/Glu buildup/depletion observed in the

cell experiments was recapitulated in the lung tumor slices but much less so for
the benign counterpart. Quantification of the

13

C-Gln and Glu from the spectra

yielded signicantly elevated Gln/Glu ratios induced by selenite in the cancerous
tissues over the benign tissues, consistent with impaired glutaminolysis (Fig.
3.5B). Downstream metabolites of
13

13

C5,15N2-Gln (13C5,15N1-Glu,

13

C4-fumarate,

C4-malate, and 13C4,15N1-Asp) were also measured in cancerous and benign

human tissue slices treated with selenite for 24 h. The reduction of labeled Glu,
fumarate, malate, and Asp in treated cancerous tissues relative to controls was
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Cancer

Benign

Figure 3.5. Effect of selenite on Gln/Glu ratio in NSCLC surgical patient tissue slices
1
A) 1D H[33] HSQC spectra recorded from polar extracts of benign and cancerous human tissue
13
15
slices labeled with C5, N2-Gln tracer and treated with or without 6.25 µM Na2SeO3 for 24 hours.
Control and selenite spectra were superimposed and normalized to total protein in order to
visualize differences between treatments. B) Gln/Glu peak area ratios were calculated. *p<0.001,
#p<0.05 for the increase in Gln/Glu in selenite treated cancer tissue slices with respect to nontreated controls and selenite treated benign tissue slices, respectively.
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not as dramatic as in the cell experiments (Fig. 3.6). Benign tissues also
responded to selenite treatment, albeit to a lesser extent, suggesting that there is
some impact on glutaminolysis in the surrounding non-cancerous tissue. Smaller
differences, however, are to be expected between tumor and benign tissue than
in pure cell culture due to the presence of stromal cells in both tissue
environments and inflammation in the lung.
3.3.2 Selenite inhibits GLS activity by decreasing its expression
Since the tracer-based metabolic characterization of SeO32- treated lung
cancer models strongly suggested inhibited glutaminolysis, I then probed the
glutaminase (GLS) activity directly by utilizing a coupled GLS-GDH colorimetric
enzyme assay (Fig. 3.7). GLS activity was significantly reduced under selenite
treatment by 6 h, which continued for 24 hours. In order to determine if enzyme
activity was modulated through direct or allosteric means, I measured GLS
activity in crude A549 lysates subsequently treated with 6.25 µM Na2SeO3 for
various times. However, only a weak dose response decrease in activity was
observed (Fig. 3.8). We then measured the specific activity of purified GAC
isoform treated with 6.25 µM Na2SeO3 and again noted no change in activity (Fig.
3.9).
In order to determine if selenite exerted its inhibitory effect via enzyme
expression, I then measured levels of the kidney (KGA) and GAC isoforms of
GLS from selenite-treated A549 cells via western blot (Fig. 3.10). Interestingly,
KGA levels remained largely unchanged while GAC expression was greatly
attenuated with the selenite treatment and undetected by 24 h, which traced the
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Figure 3.6. Quantitation of selenite effects on Gln derived metabolites in in NSCLC surgical
patient tissue slices
Polar metabolites were extracted and quantified from tumor and adjacent benign tissue slices
13
15
incubated with C5, N2-Gln and treated with or without 6.25 µM Na2SeO3 for 24 hours.
Downstream metabolites of Gln were quantified via GC-MS and normalized to total protein before
determining ratios. *’s represent a significant reduction in the selenite-treated cells compared to
non-treated controls for the designated tissue type. *p<0.05; n=3

Figure 3.7. Time course changes in GLS activity of control and SeO3 treated A549 cells
A549 cells were treated with or without 6.25 µM Na2SeO3 and harvested at 0, 1.5, 3, 6, 11, and
24 h after treatment. Mitochondria were isolated and assayed for GLS activity as described.
Activity was normalized to total protein determined via BCA. *p<0.05; n=3
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Figure 3.8. Time course changes in GLS activity of selenite-treated A549 cell lysate
A549 lysates were pooled and treated with increasing concentrations of Na2SeO3 for 0, 3, 6, 10,
and 24 h before assaying for GLS activity. Activity was normalized to total protein determined via
BCA. Single experiment.

Figure 3.9. Effect of selenite on purified GAC activity
5 mg of purified GAC were treated with increasing concentrations of Na2SeO3 for 0, 3, 6, 10, and
24 h before assaying for activity as described. Single experiment.
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Figure 3.10. Effect of selenite on GAC and KGA expression in A549
A549 cells were treated with or without 6.25 µM Na2SeO3 and harvested 0, 1.5, 3, 6, 9, and 24 h
after treatment. Protein was extracted and processed for GLS expression as described. A)
Representative western blot from selenite-treated A549 time course experiment illustrating GAC
and KGA expression. B) Quantification of GAC and KGA normalized to α-tubulin and expressed
as selenite/CTL ratio from three separate experiments.
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activity measurements shown in Figure 3.7. GAC and KGA expression was then
measured in selenite-treated NHBE cells to determine if the effect matched that
seen in A549 (Fig. 3.11). In agreement with the NMR spectra from figure 3.1
GAC expression was unchanged by selenite; however, baseline expression was
decreased relative to A549, suggesting that cancer cells may require increased
levels of GAC for proliferation. Furthermore, the data also imply that reduction of
GAC expression may be partly responsible for the cancer-specific cytotoxicity
observed with selenite treatment. Finally, I then examined GAC and KGA
expression in selenite-treated tumor and adjacent benign tissue slices.
Interestingly, the GAC expression was dramatically reduced in both tumor and
adjacent benign tissue by selenite, recapitulating the A549 response and
suggesting that GAC loss and/or glutaminolysis in the benign tissue is not as
damaging as it is in tumor (Fig. 3.12). Furthermore, KGA expression was
essentially unchanged by selenite treatment as in A549 cells. Despite unchanged
KGA expression, the increased Gln/Glu ratio in figure 3.5 suggests that adequate
glutaminase activity was not being supplied.
Total RNA was then harvested from parallel selenite-treated A549 time
course experiments in order to quantify KGA and GAC mRNA via RT-qPCR and
to determine if the decrease in GAC expression was transcriptionally regulated
(Fig. 3.13). However, no difference in KGA or GAC mRNA relative to
housekeeping gene β-actin was noted between control and selenite-treated cell
samples.
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Figure 3.11. Effect of selenite on GAC and KGA expression in NHBE
NHBE and A549 cells were treated with or without 6.25 µM Na2SeO3 and harvested 24 h after
treatment. Protein was extracted and processed for GLS expression as described. A)
Representative western blot from selenite-treated A549 and NHBE cells illustrating GAC and
KGA expression. B) Quantification of GAC and KGA normalized to α-tubulin and expressed as
selenite/CTL ratio from three separate experiments.
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3.3.3 Selenite-induced glutathione perturbations and ROS damage
As selenite is known to induce oxidative stress, GSSG/GSH ratios were
also measured from the NMR spectra of selenite-treated A549 polar extracts as
indicators of oxidative stress. The GSSG/GSH ratio was ~4-fold higher than
controls after 24 h of selenite treatment in A549 cells (Fig. 3.14). Mitochondrial
and ROS fluorescence were also measured in micrographs of selenite-treated
A549 cells as another indicator of oxidative damage (Fig 3.15). ROS
accumulation was evident as early as 3 h and increased dramatically by 24h.
3.3.4 Glu rescue experiment
We then postulated that the decrease in GAC expression and consequent
depletion of Glu and downstream metabolites induced by selenite was
responsible for the decreased total glutathione levels, increased GSSG/GSH
ratios, and increased ROS production. In order to test this hypothesis we treated
A549 cells with 6.25 µM Na2SeO3 in the presence or absence of 5 mM Glu. By
supplying the cells with the direct product of the GAC reaction we expected to
mitigate the anti-proliferative effects of selenite. Indeed, in the presence of Glu,
the proliferation of selenite-treated A549 cells was substantially rescued, as
measured via Janus green proliferation assay (Fig. 3.16). Interestingly, Glu
appeared to stimulate control growth above baseline.
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Figure 3.12. Effect of selenite on GAC and KGA expression in NSCLC surgical patient
tissue slices
A) Representative western blot from selenite-treated tumor (T) and adjacent benign (B) NSCLC
patient tissue. B) Quantification of GAC and KGA normalized to tubulin and expressed as SeO3
2
/CTL ratio from four separate patients.
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Figure 3.13. Relative fold change of KGA and GAC mRNA.
A549 cells were treated with or without 6.25 µM Na2SeO3 and harvested at 0, 1.5, 3, 6, 11, and
24 h after treatment. Total RNA was extracted and measured as described. ddCt values were
calculated with b-actin as housekeeping gene. Fold changes were then calculated and are shown
2as SeO3 /CTL relative changes.

Figure 3.14. Quantitation of GSSG/GSH in selenite treated A549 cells
1D proton spectra were recorded from the polar extracts of A549 cells treated with or without 6.25
µM Na2SeO3 for 24 hours. GSSG and GSH were quantified, and GSSG/GSH was calculated.
*p<0.01; n=3
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Figure 3.15. Effect of selenite on ROS in A549 cells
A549 cells were treated with or without 6.25 µM Na2SeO3 and prepared for ROS measurement as
described at 3, 6, 24, and 48 h after treatment as described. Red stain indicates mitochondria and
green stain indicates DCHDFA oxidation as a measure of ROS production.

Figure 3.16. Glu rescues the proliferative phenotype in selenite-treated A549 cells
A549 cells were treated with or without 6.25 µM Na2SeO3 +/- 5 mM Glu and measured for growth
via Janus green assay 0, 1, 2, and 3 days after treatment as described. Fractional growth was
calculated as the absorbance at day n divided by absorbance at day 0. Fractional growth is
plotted as selenite-treated cells +/- Glu divided by the fractional growth of non-treated controls.
*p<0.001; n=5
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3.4 Conclusions
These experiments illustrate a novel mechanism for selenite-induced ROS
accumulation in A549 cells. Examination of the metabolic profiles generated from
selenite-treated A549 showed significantly elevated Gln and depleted Glu
consistent with decreased glutaminase activity. This effect on glutaminase was
selective towards cancer cells as Gln and Glu levels in non-transformed NHBE
cells were substantially less affected. By utilizing a tracer-based experimental
design with

13

C5,15N2-Gln we then showed that anapleurosis of the TCA cycle

through glutaminolysis was dramatically attenuated by selenite treatment.
Depletion of labeled glutaminolytic metabolites from

13

C5,15N2-Gln occurred

rapidly within 3 hours of treatment. We then repeated these experiments in an
individualized lung cancer tissue slice model, which recapitulated impaired
glutaminolysis substantially moreso in the cancer than in the adjacent benign
tissue. Treatment with selenite caused a time-dependent decrease in GAC
protein expression without impacting transcription levels or enzyme specific
activity indicating that selenite affects either the translation or degradation rate.
Interestingly, KGA was unchanged by selenite treatment suggesting that the
GAC splice variant is vital for cancer growth and viability. Furthermore, GAC
expression was also decreased in selenite treated tissue slices from four
separate NSCLC patients.
Gln is one of the main anapleurotic substrates contributing towards
anabolism including glutathione synthesis. We showed that selenite treatment
substantially decreased newly synthesized glutathione as well as increased the
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ratio of GSSG/GSH. Presumably, the decrease in glutathione synthesis stems
from impaired glutaminolysis which is needed to supply glutamate, and could
contribute towards increased GSSG/GSH as reduced glutathione is consumed.
As A549 cells rapidly proliferate, GSH must be synthesized continually in order to
maintain steady-state levels and replenish stores lost through non-oxidative
means; however, selenite blocks this process by inhibiting glutaminolysis.
Increased ROS production in the presence of selenite overwhelms the capacity
of the GPX/GR/NADPH systems, leading to increased GSSG/GSH.

The

resulting high ROS may initiate autophagic and apoptotic pathways, further
increasing ROS [22]. Preventing this cascade of events would require providing
the necessary reducing equivalents for the surge in ROS. Park et al. [22] showed
that exogenous NAC supplied these reducing equivalents; however, we found
that supplying the cells with Glu restored proliferation as well. This suggests that
impaired glutaminolysis via decreased GAC expression is one of the primary
sources for escalating ROS production and selenite mediated cell death.
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CHAPTER 4-GLYCOGEN IS AN IMPORTANT FUEL
SOURCE FOR LUNG CANCER
4.1 Introduction
Glycogen is a polymeric storage form of glucose in mammalian tissues,
particularly in liver and skeletal muscle. It is a highly branched polymer,
comprising linear chains of α−1,4 linked glucose subunits, with α-1,6 branch
points, and is stored in granules in the cytoplasm. Glycogen synthesis consumes
an ATP equivalent (via the activation step of G1P+UTP->UDPGlc + Pi).
Glycogen is mobilized through glycogenolysis via glycogen phosphorylase (PYG)
and the debranching enzyme, which can liberate glucose-1-phosphate (G1P)
during fasted or exerted states when blood glucose is low. G1P is readily
isomerized to G6P without the consumption of ATP. Thus, glycogenolysis
followed by glycolytic transformation to pyruvate generates 3 ATP molecules per
molecule of glucose oxidized.
Glycogen metabolism is generally tightly regulated through both insulin
and epinephrine-dependent and independent mechanisms acting reciprocally
through glycogen synthase and glycogen phosphorylase [86]. There is a wellcharacterized clinical history of disorders in glycogen metabolism typically
classified as the glycogen storage diseases. Glycogen storage diseases typically
manifest with varying clinical severity and a pathophysiology stemming from
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mutations in the three main isoforms of glycogen phosphorylase (GPase), which
are the brain or fetal (PYGB), liver (PYGL), and muscle (PYGM) variants [87, 88].
Glycogenolysis is also of burgeoning interest in the context of cancer
metabolism. PYGB was the main isoform expressed in 59 cancer cell lines
including A549, whose growth was reduced via pharmacological inhibition of
PYGB [89]. Furthermore, glycolytic models have indicated that glycogen
degradation is an integral process for controlling flux through glycolysis under
glucose-deprived tumor environments [90]. Glycogenolysis also seems to be
closely tied to UDP-GlcNAc regulation as was illustrated by a glycogen-derived
increase in O-GlcNAc modification of proteins in response to glucose deprivation
[50]. Furthermore, the brain isoform of GPase is less sensitive to regulation by
phosphorylation than either the liver or muscle isoforms, but is strongly activated
by AMP, making it an energy-sensing enzyme [29]
In order to further elucidate the anti-cancer potential of glycogen
phosphorylase inhibition and obtain detailed understanding of its metabolic basis
I utilized SIRM-based experimental design to evaluate the metabolic effect of
PYGB suppression in A549 cells. This target was also chosen to follow up on the
reduction of glycogen synthesis that was observed in selenite-treated lung
cancer tissue. I chose to focus on PYGB because it is the isoform that is primarily
expressed in A549 cells and its relevance with regards to growth inhibition in
cancer cells [91]. Finally, its role in UDP-GlcNAc metabolism is unclear and thus
a worthwhile target for further investigation.
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4.2 Methods
Cell culture: A549 and 293T cells were grown in glucose-free, glutamine-free
DMEM medium supplemented with 10% FBS, 0.2% (A549) or 0.45% (293T)
glucose, 4 mM glutamine, and 100 I.U./mL penicillin 100 µg/mL streptomycin at
37 °C and 5% CO2. For tracer experiments, cells were grown to ~70%
confluence, and medium was aspirated and replaced with the tracer medium
containing 0.2%

13

C6-glucose (10.8 mM) (Sigma Isotec, St. Louis. MO). For

western blots, cells were lysed directly on the plate using 62.5 mM Tris, 2% SDS
buffer at pH 6.8 before harvest by scraping and protein concentration was
measured via the BCA method (Pierce).

Lentiviral PYGB suppression: 293T cells generously donated by Dr. Mariia
Yuneva were grown to ~50% confluence in 6-well plates before transfecting with
shRNA constructs. One h prior to transfection, medium was replaced with fresh
medium. 0.3 µg pMDG (Yuneva), 0.6 µg pCMV (Yuneva), 1.2 µg shRNA, and 10
µL X-tremeGENE HP transfection reagent (Roche, Mannheim, Germany) were
mixed with OPTIMEM (Invitrogen) medium to a total volume of 110 µL per well
(6-well plate) and incubated for 20 min at room temperature before applying to
wells dropwise. shPYGB’s and the empty vector (shEV,Mission® shRNA, Sigma,
St.

Louis,

MO).)

(Sigma)

had

the

following

sequences:

sh339,

CCGGGCTATGGAATCCGCTATGAATCTCGAGATTCATAGCGGATTCCATAG
CTTTTTTG; sh479, CCGGGATCGTGAAACAGTCGGTCTTCTCGAGAAGACCG
ACTGTTTCACGATCTTTTTTG; sh010, CCGGCACGAAGAAGACCTGTGCATA
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CTCGAGTATGCACAGGTCTTCTTCGTGTTTTTTG. About 12 h after applying
transfection reagents, medium was again replaced with fresh medium.
Transduction of A549 cells occurred ~48 h after transfection of 293T cells. In
preparation, A549 cells were grown to ~50% confluence and medium was
replaced immediately prior to transduction. Viral medium from 293T cells was
collected and filtered using a 0.22 µm syringe filter before adding 16 µg/mL
polybrene (Sigma). The filtered medium was then applied to wells dropwise
(polybrene final concentration, 8 µg/mL). Fresh medium was added to
transfected 293T cells for repeating the transduction procedure 24 h later. After
24 h of the final transduction, A549 medium was replaced with fresh medium. 4872 h after transduction, A549 cells were selected using medium supplemented
with 1 µg/mL puromycin (Sigma).

Proliferation assays: Proliferation of A549 cells was measured in 96-well plates
according to the protocol by Raspotnig et al. [64]. Briefly, at the time of
measurement, cell medium was aspirated and replaced with 50% ethanol in H2O
for 30 min. Ethanol was then aspirated and replaced with minimal volume of
0.2% Janus green dye in PBS for 5 min. Dye was aspirated and plates were
rinsed in tap H2O and drained by gravity. Dye was then dissolved in 0.5 N HCl
and absorbance was measured at 595 nm at 0, 24, 48, and 72 h of growth.
Growth was reported as the fraction of the absorbance at a given time point
divided by the absorbance at 0 h.
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Colony formation assay: One % agarose in H2O was melted in a microwave to
sterilize and then mixed with equal volumes of pre-warmed 2X DMEM cell culture
medium. One mL of the mixture was then quickly added to each well of a 6-well
culture plate and allowed to solidify at room temperature. After bottom layer had
solidified, 3% agarose in PBS was melted in a microwave and allowed to partially
cool. Cells to be assayed were trypsinized, counted, and diluted to 11,000
cells/mL in pre-warmed DMEM culture medium. The cell suspension was then
quickly mixed with 3% agarose at a ratio of 10:1 suspended cells:agarose, and 1
mL of the resulting mixture was immediately added on top of the bottom agarose
layer without disruption of the bottom layer or bubble formation. The top layer
was then allowed to solidify for 30-60 min at room temperature. After
solidification, 1 mL of DMEM culture medium was then carefully added to each
well to avoid disturbing the agarose. Once a week, medium was carefully
replaced via aspiration, again to avoid agarose disruption. After ~2 weeks or
when colonies had grown sufficiently, medium was aspirated and wells were
stained with 0.005% crystal violet in PBS for >1 h. Colonies (>8 aggregated cells)
were digitally documented for colony size and shape and counted for 20 random
fields of view.

Extraction of metabolites: Transduced A549 cells were seeded in 10 cm plates
and grown until the shEV-transduced cells reached ~90% confluence for harvest.
At the time of harvest, medium was collected before all plates were washed three
times with ice cold PBS, and PBS was removed as much as possible by
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aspiration. The cells’ metabolism was then quenched with 1 ml of CH3CN kept at
-20°C before 0.75 ml of nanopure water was added and cells were harvested by
scraping. The process was repeated once before CHCl3 addition to a final
CH3CN:H2O:CHCl3 ratio of 2:1.5:1 to obtain the polar, non-polar and insoluble
proteinaceous interface fractions for downstream analysis [65, 66]. For
metabolite extraction from the medium, protein was first precipitated in ice-cold
10% trichloroacetic acid (TCA), and supernatant was lyophilized immediately to
remove the acid. Since some metabolites such as glutamine are sensitive to
prolonged storage in acidic conditions, metabolite analysis of medium samples
by NMR or GC-MS was performed immediately after lyophilization.

NMR experiments: All NMR experiments were conducted on a Varian Inova 14.1
T instrument equipped with 5 mm HCN cold probe. Cell and medium extracts
were dissolved in D2O with 30 and 50 nmol d6-DSS, respectively, as internal
standard. Shigemi tubes were used for polar extracts to minimize sample volume
and thus to concentrate the metabolites. 1D proton spectra were recorded with
an acquisition time of 2 seconds after initial presaturation of the H2O signal with a
recycle time of 5 seconds. 1D

13

C-filtered HSQC spectra were measured using

an acquisition time of 150 ms. 1D proton spectra were processed using a 1 Hz
exponential line broadening function and a zero fill of 128 k points. 1D 13C-filtered
HSQC spectra were processed with a 6 Hz line-broadening exponential and 0.07
Hz Gaussian functions and zero filled to 16 k points. Both types of spectra were
processed manually for baseline and phase corrections. 1D proton spectra were
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referenced using the methyl signal of D6-DSS at 0 ppm, and 1D

13

C-filtered

HSQC spectra were referenced to the C3-lactate peak at 1.32 ppm and 1.41 ppm
for cell and medium extracts, respectively. Metabolites were identified in
reference to an in-house standard database and quantified by calibration with the
methyl resonance of the DSS internal standard using the MestReNova NMR
processing software (Mestrelab Research, Santiago de Compostela, Spain) [59].

GC-MS analysis: An aliquot of the lyophilized extracts was derivatized in 50% Ntert-Butyldimethylsilyl-N-methyltrifluoroacetamide

with

1%

tert-

Butyldimethylchlorosilane (MTBSTFA + 1% TBDMSCl) in CH3CN before GC-MS
analysis. All GC-MS data were acquired on a ThermoFinnigan PolarisQ GC-Ion
trap MSn instrument (ThermoScientific, Rockford IL). One µL of the derivatized
sample was separated on a SGE Forte (Victoria, Australia) 5% phenyl capillary
column with the following dimensions: 50 m x 0.15 mm; 0.25 µm film thickness.
The GC parameters were as follows: injector and transfer line, 280 °C; oven, 60
°C for 2 min, 60 to 150 °C at 20 °C/min ramp, 150 to 300 °C at 6 °C/min ramp;
He carrier gas with flow rate of 1.5 mL/min. Spectra were acquired in segscan
mode with ranges of 140-206, 209-280, and 283-650 m/z with an acquisition time
of 0.97 s. Spectra were processed using Xcalibur MS software and quantified
using a mixture of 63 standards at 50 µM each except for glutamate at 500 µM.
All samples and standards were spiked with 1 µM norleucine as internal
standard.
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Nucleotide

processing

for

FT-ICR-MS

(Fourier

transform-ion

cyclotron

resonance-mass spectrometry) analysis: Nucleotides were ion-paired with
hexylamine and extracted from polar extracts as described previously [57].
Briefly, dried extract aliquots (e.g. 1/16 of one 10 cm plate) were dissolved in 5
mM hexylamine in H2O (buffer A) with the pH adjusted to 6.3 with acetic acid.
Dissolved nucleotides were adsorbed onto C18 ZipTips (Millipore, Billerica, MA)
pre-conditioned with MeOH and buffer A. Bound nucleotides were then washed
with buffer A followed by elution with 70% buffer A/30% buffer B (90% methanol
and 10% 10mM ammonium acetate adjusted to pH 8.5 with aqueous ammonia).
Eluent was then lyophilized and reconstituted in 2:1 MeOH:buffer B for FT-ICRMS analysis.

FT-ICR-MS analysis: FT-ICR-MS analysis was performed as described
previously [57]. Briefly, data were recorded on a hybrid linear ion trap–FT-ICR
mass spectrometer (Finnigan LTQ FT, Thermo Electron, Bremen, Germany)
using an automated nanospray ion source (TriVersa NanoMate, Advion
BioSciences, Ithaca, NY) set with an “A” chip run at 1.5 kV and 0.5 psi head
pressure. Measurements were recorded for 15 min, which consisted of 14 min of
high resolution FT-ICR scans, followed by 30 s of low resolution ion trap scans
(LTQ). FT-ICR-MS scans were recorded from 150-800 Da with a mass resolving
power set to 400,000 at 400 m/z. Each transformed spectrum consisted of 5
summed transients at 2 s per transient for a cycle time of 10 s. All FT-ICR-MS
scans were summed to produce the final spectrum. Spectra were then exported

	
  
117	
  

via Xcalibur MS software and peaks were corrected and assigned using an inhouse software (PREMISE [56]).

Western Blot: At time of harvest cells were lysed directly on the plate using 62.5
mM Tris, 2% SDS buffer at pH 6.8 before harvest by scraping, and protein
concentration was measured via the BCA method (Pierce). All protein extracts
were diluted in 4X loading buffer (50% glycerol, 4% SDS, 150 mM Tris pH 6.8, 1
mM DTT, 0.02% bromophenol blue, 10% β-mercaptoethanol) to 1X strength and
then boiled for 10 minutes prior to electrophoresis. Approximately 30 µg protein
was loaded for each sample onto a denaturing SDS 10 % acrylamide gel with a
6% stacking gel. Protein extracts were stacked for 30 min at 100 V and then
resolved for 1.5 h at 200 V using commercially available Tris/Gly/SDS buffer
(National Diagnostics, Atlanta, GA). Proteins were then transferred onto a PVDF
membrane (Immobilon-P, Millipore, Bedford, MA) at 25 V for 2 h at room
temperature in an Invitrogen transfer apparatus. The transferred membrane was
then incubated in the following primary antibody at 4 °C on a rocker overnight:
PYGB (LSBio, Seattle, WA), 1:1000 in PBST with 5% BSA; α-tubulin (epitomics),
1:50,000 in PBST with 5% non-fat powdered milk. Membranes were then washed
3 times with PBST before incubating 1 hour at room temperature with an HRPconjugated secondary antibody (Pierce, 1:2000 in PBST with 5% non-fat
powdered milk). Blots were then incubated in Pierce supersignal extended
duration chemiluminescent reagent before exposure to x-ray film (SCBT) for
visualization.
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4.3 Results and discussion
4.3.1 PYGB suppression inhibits growth and colony formation in A549 cells
In order to determine if glycogen metabolism is important for supporting
cancer cell proliferation, PYGB suppression in A549 cells was achieved using
lentiviral transduction system and shPYGB vectors. Three different vectors were
tested for their efficiency in PYGB suppression and effect on cell growth as
shown in figure 4.1A. Sh339 and sh479 had the greatest effect on PYGB
expression, while sh010 had much less impact (Fig. 4.1B). However, all three
vectors had similar effects on proliferation, and by 72 h growth was attenuated by
about 100%. Interestingly, sh010 exerted the strongest effect on proliferation
despite having a slight effect on PYGB expression suggesting an off target
mechanism of growth reduction. Colony formation assay was also performed as
a surrogate analysis for tumorigenesis with these three vectors (Fig. 4.2). Sh479
but not the other two vectors had a small but significant effect on colony
formation, reducing the number of colonies by ~30% suggesting that PYGB may
also be involved in tumorigenesis but has a greater effect on growth.
4.3.2 PYGB-suppressed A549 cells accumulate glycogen and glucose
The metabolic perturbations in these suppressed cells were investigated
using

13

C6-glucose as a tracer. The NMR spectra of polar metabolites for

shPYGB and shENV samples showed a noticeable accumulation of unlabeled
glycogen (5.4 ppm) and glucose (5.22 ppm) in sh339 and sh479-suppressed
cells relative to controls as shown in figure 4.3. Newly synthesized glucose (e.g.
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Figure 4.1. PYGB suppression inhibited A549 cell growth
A549 cells were transduced with three different lentiviral shPYGB constructs along with an empty
vector (shENV) as described in Methods. Growth was measured via Janus green assay five
passages after transduction. Growth was plotted as fraction relative to day 0. B) PYGB
expression in A549 cells 5 passages after transduction.
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Figure 4.2. PYGB suppression reduced A549 colony formation
ShPYGB transduced A549 cells were assayed for colony formation after five passages. Bars
represent the average number of colonies from 20 field views measured in biological duplicates.
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Figure 4.3. PYGB suppressed A549 cells accumulated glycogen and glucose
13
5 passages after shPYGB suppression, A549 cells were incubated with C6-glucose for 24 h.
Polar metabolites were extracted and measured via 1D proton NMR. Spectra were normalized to
total protein for visualizing differences in glycogen and glucose content.
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13

C1-glucose at 5.22 ppm) and glycogen (13C1-glycogen at 5.4 ppm) also

accumulated in sh339 and sh479-transduced cells relative to the control cells as
shown in the protein normalized HSQC spectra, which suggests increased
glycogen synthesis and/or decreased utilization (Fig. 4.4). The latter is expected
from the block of GPase activity from the PYGB knockdown. However, the NMRobservable glycogen peak only represents the freely mobile reducing ends of
glycogen, which may not fully represent the status of bulk glycogen. Namely,
some of these C1-protons may be immobilized within the interior of the molecule
and are not observable in 1H NMR analysis.
Thus, to better visualize the total glycogen pool in these crude extracts,
the extracts were hydrolyzed with 1M HCl at 65 °C for 10 min. Total glycogen
was hydrolysed to free glucose, which was quantified by the peak at 5.22 ppm in
the 1H NMR spectra. As shown in figures 4.5 and 4.6, there was an increase in
the H1 glucose peak at 5.22 ppm in both the 1D proton and 1D

13

C-filtered

HSQC spectra of sh339 and sh479-suppressed cells, indicating glycogen buildup
as expected with PYGB suppression. However, the effect of sh010 transduction
differed, i.e. a significant increase in the level of acid-liberated
not in that of

13

12

C-glucose but

C-glucose. This pattern suggests a buildup of unlabeled glycogen

but not newly synthesized

13

C-labeled glycogen consistent with a block in both

glycogen hydrolysis and synthesis. Altogether, these data demonstrate selective
suppression of PYGB by sh339 and sh479, while sh010 suppressed PYGB less
while having non-targeted suppression of glycogen synthesis.
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Figure 4.4. PYGB suppressed A549 cells accumulated newly synthesized glycogen in A549
13
5 passages after shPYGB suppression, A549 cells were incubated with C6-glucose for 24 h.
13
Polar metabolites were extracted and measured via C-filtered 1D HSQC NMR. Spectra were
normalized to total protein in order to visualize differences in glycogen and glucose.
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Figure 4.5. Hydrolysis of polar extracts from shPYG suppressed A549 cells liberated
unlabeled glucose units from glycogen
13
5 passages after shPYGB suppression, A549 cells were incubated with C6-glucose for 24 h.
Polar metabolites were extracted and glycogen was hydrolyzed as described. HCl-liberated
glucose was measured via 1D proton NMR, and spectra were normalized to total protein in order
to visualize differences.
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Figure 4.6. Hydrolysis of polar extracts from shPYG suppressed A549 cells liberated
labeled glucose units from glycogen
13
5 passages after shPYGB suppression, A549 cells were incubated with C6-glucose for 24 h.
Polar metabolites were extracted and glycogen was hydrolyzed as described. HCl-liberated
13
glucose was measured via C-filtered 1D HSQC NMR, and spectra were normalized to total
protein in order to visualize differences.
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Because there was an increase in intracellular glucose levels with PYGB
suppression, lactate production and glucose consumption were also measured in
the medium, as shown in figures 4.7A and B, respectively.

13

C6-glucose levels

remained higher in the media of the PYGB-suppressed cells, particularly cells
with sh339 and sh479 constructs. However,

13

C-latate released into the medium

was comparable for all experimental groups. The lower glucose consumption
elicited by PYGB suppression can be attributed to slower proliferation as well as
the block in glycogen utilization leading to the accumulation of newly synthesized
glycogen (Fig. 4.6). In the latter case, glycogen synthesis could be a substantial
sink for glucose utilization in A549 cells. Taken together, glycogen is an
important fuel for supporting cancer cell growth.
4.3.3 PYGB suppression reduces Krebs’ cycle activity
In order to determine the effect of PYGB suppression on Krebs’ cycle
metabolism in A549 cells, Krebs’ cycle metabolites and their 13C labeling patterns
from the

13

C6-glucose tracer experiments were quantified using GC-MS. PYGB

suppression, particularly with the sh479 vector, attenuated the total levels of
citrate, fumarate, malate, and succinate as shown in figure 4.8. In addition,

13

C

incorporation from labeled glucose into doubly labeled (13C2) Asp, fumarate,
malate, and succinate were significantly reduced primarily in sh479-suppressed
cells. These data are consistent with a reduced flux through the Krebs’ cycle in
sh479-transduced cells (Fig. 4.9). A similar reducing trend was also observed in
the levels of many amino acids as shown in figure 4.10, again with the sh479
transduction having the greatest effect (2-3 fold changes). This effect of PYGB
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Figure 4.7. PYGB suppression reduces glucose consumption
13
5 passages after shPYGB suppression, A549 cells were incubated with C6-glucose for 24 h.
13
Polar metabolites of the medium were extracted and measured via 1D proton NMR. Medium C313
lactate (A) and C1-glucose (B) resonances were quantitated and normalized to total protein.
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Figure 4.8. PYGB suppression decreases the level of Krebs’ cycle intermediates
13
5 passages after shPYGB suppression, A549 cells were incubated with C6-glucose for 24 h.
Polar metabolites were extracted and measured via GC-MS, and Krebs’ cycle intermediates were
quantified and normalized to total protein. Data are represented as the fraction of metabolite in
the designated shPYGB construct over that in shENV.

Figure 4.9. PYGB suppression decreases flux through the TCA cycle
13
5 passages after shPYGB suppression, A549 cells were incubated with C6-glucose for 24 h.
Polar metabolites were extracted and measured via GC-MS, and TCA cycle isotopologues were
13
quantified and normalized to total protein. Data are represented as the fraction of C2-metabolite
in the designated shPYGB construct over that in shENV.
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Figure 4.10. PYGB suppression reduces amino acid levsel
13
5 passages after shPYGB suppression, A549 cells were incubated with C6-glucose for 24 h.
Polar metabolites were extracted and measured via GC-MS, and amino acids were quantified
and normalized to total protein. Data are represented as the fraction of metabolite in the
designated shPYGB construct over that in shENV.
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suppression on amino acids could be related to reduced synthesis of nonessential amino acids (Fig. 4.11).
4.3.4 PYGB suppression blocks nucleobase synthesis in A549 cells
13

C incorporation into nucleotides was also measured by FT-ICR-MS to

determine the effect of PYGB suppression on nucleotide synthesis. The
UTP isotopologue corresponds to the fully
isotopologues with >5

13

13

13

C5 -

C labeled ribose subunit while

C atoms (13C6-8 in Fig. 4.12) represent additional

13

C

incorporation into the uracil ring via the aspartate precursor derived from Krebs’
cycle OAA. Labeling of the ribose subunit was unaffected by the knockdown,
whereas labeling of the uracil ring was significantly attenuated by PYGB
suppression, especially for 2 and 3

13

C atoms entering the uracil ring, which

showed a 30-40% reduction in PYGB suppressed cells compared with control
cells. Again, the sh479 construct had the greatest effect (Fig. 4.12). The
percentage of unlabeled UTP (13C0-UTP) was also increased by PYGB
13

suppression, consistent with reduced incorporation of
with decreased synthesis of its precursor Asp from

13

C into the uracil ring and

C6-glucose (cf. Fig. 4.9). A

related sugar nucleotide UDP-N-acetylglucosamine (UDP-GlcNAc) showed
reduced fractional enrichment in the more extensively labeled isotopologues (e.g.
13

C14-16-UDP-GlcNAc in Fig. 4.13) but increased fractional enrichment in the less

extensively labeled isotopologues (e.g.

13

C5 ,

13

Unlabeled UDP-GlcNAc was absent by 24 h.

C6, and
13

13

C5 and

C11-UDP-GlcNAc).
13

C6-UDP-GlcNAc

isotopologues most likely each corresponds to complete enrichment of the ribose
and glucosamine subunit, respectively, while 13C11-UDP-GlcNAc likely represents
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Figure 4.11. PYGB suppression reduces amino acid synthesis
13
5 passages after shPYGB suppression, A549 cells were incubated with C6-glucose for 24 h.
Polar metabolites were extracted and measured via GC-MS, and amino acids were quantified
and normalized to total protein. Data are represented as the fraction of unlabeled isotopologue
divided by the total amount.

Figure 4.12. PYGB suppression reduces uracil synthesis
13
5 passages after shPYGB suppression, A549 cells were incubated with C6-glucose for 24 h.
Nucleotides were extracted and measured via FT-ICR-MS. Fractional distribution of 13C
isotopologues of UTP were quantified and are represented as the fraction of UTP isotopologue in
the designated shPYGB construct overthat in shENV.
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Figure 4.13. Effect of PYGB suppression on UDP-GlcNAc enrichment
13
5 passages after shPYGB suppression, A549 cells were incubated with C6-glucose for 24 h.
Nucleotides were extracted and measured via FT-ICR-MS. UDP-GlcNAc isotopologues were
quantified and are represented as the fraction of UDP-GlcNAc isotopologue in the designated
shPYGB construct over shENV.
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labeling in both subunits.

13

C14-16-UDP-GlcNAc isotopologues then reflect

labeling in the uracil ring and/or the acetyl unit [92]. Therefore, the reduced
labeling in the 13C14-16 isotopologues indicates decreased enrichment of the uracil
and/or acetyl subunits, consistent with attenuated UTP ring synthesis and Krebs’
cycle activity (Fig. 2.18). Finally,

13

C6-glucose incorporation into ATP showed

selective attenuation in the fractional enrichment of

13

C6-7-ATP relative to

13

C5 -

ATP with PYGB suppression, again suggesting decreased enrichment in the
adenine ring (Fig. 4.14). Carbon in the adenine ring is derived from either Gly or
N10-formyl tetrahydrofolate (THF), the latter of which can be synthesized from Gly
or Ser and ultimately from glucose (Fig. 4.15). Gly and Ser levels were reduced
by PYGB suppression (cf. Figs. 4.10, 4.16), which is consistent with a decrease
in their incorporation into the adenine ring and thus, purine synthesis. Taken
together, all of the above nucleotide data point to no effect from PYGB
suppression on ribose incorporation.

4.4 Conclusions
This study has shown that lung cancer cells have the capacity to
synthesize and utilize glycogen in the presence of abundant glucose supply. The
expression of the fetal form of glycogen phosphorylase (PYGB) and the
phenotypic consequences of its knockdown on A549 cells demonstrated the
importance of glycogen utilization for lung cancer cell proliferation, and to some
extent tumorigenesis. Parallel SIRM investigations reveal perturbations in the
Krebs cycle activity, nucleobase synthesis, and amino acid metabolism that may
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Figure 4.14. Effect of PYGB suppression on ATP enrichment
13
5 passages after shPYGB suppression, A549 cells were incubated with C6-glucose for 24 h.
Nucleotides were extracted and measured via FT-ICR-MS. ATP isotopologues were quantified
and are represented as the fraction of ATP isotopologue in the designated shPYGB construct
over shENV.
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Figure 4.16. PYGB suppression reduces Gly and Ser synthesis
13
5 passages after shPYGB suppression, A549 cells were incubated with C6-glucose for 24 h.
Polar metabolites were extracted and measured via GC-MS, and amino acids were quantified
and normalized to total protein. Data are represented as the fraction of unlabeled isotopologue
divided by the total amount.
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underlie the phenotypic changes. These results highlight the need for continued
investigation into the role of glycogen metabolism and PYGB in particular in other
cancer models and the notion that PYGB is worthy to pursue as a new target for
cancer chemotherapeutics. Specifically, the individualized lung cancer models
detailed in chapter 2 are ideal candidates for probing the effects of glycogen
inhibitors of lung cancer metabolism. We are currently utilizing this approach in
our ongoing patient study.
It is worth noting that sh479 had the clearest effect of metabolic disruption
linked to A549 growth attenuation and reduced colony formation. This effect was
smaller with sh339 suppression and in all regards anomalous with sh010 as its
suppression of PYGB was minimal. Furthermore, formation of colonies was
reduced by PYGB suppression via sh479, suggesting that PYGB is partially
necessary for tumorigenesis, but likely more important in the setting of tumor cell
growth

and/or
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survival.

CHAPTER 5-CONCLUSIONS
The central thesis at the core of this study was that the anti-cancer
mechanism of selenite could be elucidated by utilizing a metabolic approach. In
order to approach this aim SIRM was extensively used to generate a
comprehensive profile of the metabolic perturbations that follow when human
lung cancer is exposed to selenite by using a combination of patient tissue and
cell-based models. These findings were then followed up with complementary
methods in order to gain a more finely detailed understanding of the specific
pathways that may be targeted by selenite. Indeed a number of pathways were
rigorously examined simultaneously using SIRM experimental design, which
underscored the viability and necessity of tracer-based design for this level of
metabolic detail.
A principal finding in the initial studies was that the activity of the TCA
cycle is dramatically reduced by selenite with a concomitant increase in glycolytic
rate in a cancer-specific manner. This increase in flux through glycolysis is
accompanied by an increase in lactic fermentation and decrease in flux through
the pentose phosphate pathway in an effort to meet the compromised energy
demands of the rapidly growing cancer cells caused by disruption of aerobic
respiration. These alterations had far-reaching effects in nucleotide and
hexosamine nucleotide synthesis and utilization. Purine and pyrimidine base
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synthesis was profoundly impacted by selenite treatment and, to a lesser extent,
ribose synthesis. Decreased synthesis of the bases was traced back to
decreased incorporation of Asp, Gly, and Gln carbon and/or nitrogen into the
purine or pyrimidine rings due primarily to a compromised Krebs’ cycle. This
attenuation was propagated in the synthesis of UDP-GlcNAc, which in turn has
downstream implications for the regulation of specific protein targets. Indeed, OGlcNAc modification of proteins was extensively decreased in selenite-treated
cells.
Unfortunately, efforts to isolate and further characterize a specific target
were met with difficulty. By isolating a protein target one could then reassess the
metabolic profile generated from selenite treatment in order to evaluate possible
downstream effects of this altered regulatory modification. As O-GlcNAcylation is
an area of burgeoning interest and relatively few targets (there are many) have
been thoroughly studied, this approach would be a worthwhile continuation of this
study, especially in the context of the individualized lung cancer models.
A likely source for the observed selenite-induced perturbations in cancer
metabolism is decreased glutaminolysis. Glutaminolysis was rapidly and
dramatically inhibited with selenite treatment, and decreased expression of GAC
was isolated as a probable source. A plausible mechanism for selenite-induced
cytotoxicity was then postulated that underscored the pivotal role of GLS in
glutathione synthesis, especially when the cell is compromised by increased
ROS and the reduction of GSSG becomes overwhelmed. Restoration of A549
growth upon supplementation with a product of GAC, Glu, was crucial towards
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solidifying this hypothesis. Furthermore, GAC expression was unchanged in noncancer cells, which alludes to a possible mechanism for the cancer-specificity of
selenite. Examining whether or not Glu supplementation also reverses ROS
accumulation would be a useful corollary for these experiments. Furthermore,
assessing the state of ROS with or without Glu supplementation in the
individualized cancer models would also generate a more compelling story. Also
what is indicated from this investigation is a thorough dissection of the
mechanism behind the decrease in GAC expression and why this effect is absent
in non-transformed cells.
Finally, an alternative pathway that was affected by selenite treatment,
glycogenolysis, was also investigated, abeit less so. Using a combination of
shRNA PYGB suppression and tracer-based design, I concluded that glycogen
was an important fuel source for lung cancer, and disruption of its utilization led
to decreased proliferation as well as tumor formation to a smaller extent. These
effects of suppression were measured in the context of a host of other metabolic
alterations that included a decrease in TCA cycle activity as well as nucleobase
synthesis. These experiments could be greatly augmented by implementation of
the individualized lung cancer models and a PYGB inhibitor, which is ongoing.
The use of individualized lung cancer models was integral towards
illustrating the translational capabilities of these experiments. A more through
inclusion of specimens from the ongoing patient study would be an exciting
project as there is a wealth of clinical data associated with these models. This
clinical information includes factors like the tumor grade, subtype, and
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environmental history of the patient from whom it was derived and correlating
these data to the metabolic profile would be a worthy endeavor.
Furthermore, these experiments illustrate the need for continued
investigation of selenite supplementation for chemopreventive or adjunctive
chemotherapeutic potential. These efforts are particular important in the context
of the negative press generated from the failed SELECT trial. Recent analyses of
traditional Inuit diets have underscored the potential health benefits of seleniumhigh diets despite the high levels of mercury and organic pollutants inherent in
these food sources [93, 94]. The in vivo efficacy of selenite has already been
demonstrated by the reduction of tumor growth in rodents (reviewed in [20]).
Clearly, these results point towards exciting future prospects for selenium
research. Continued accrual and analyses of NSCLC patients as demonstrated
would likely bolster these overall conclusions. In the future, it is imperative that
the focus of more targeted studies and/or trials involves seleno-compounds with
known anti-cancer efficacy over ineffective species, such as selenomethionine.
Finally, exposure to the breadth and quality of scientific analyses possible
by taking advantage of NMR, MS, and molecular biological methods has itself
been integral for the fruition of this thesis. The opportunities possible for
metabolic research in the context of tumor biology and beyond are numerous and
exciting, and this study comprises a small portion of that potential.
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APPENDIX
List of abbreviations
TCA cycle: tricarboxylic acid cycle
NMR: nuclear magnetic resonance
MS: mass spectrometry
GC-MS: gas chromatography-mass spectrometry
FT-ICR-MS: Fourier transform-ion cyclotron resonance-mass spectrometry
NSCLC: non-small cell lung cancer
UDP-GlcNAc: uridine diphospho-N-acetylglucosamine
NHBE: normal human bronchial epithelial
KGA: glutaminase, kidney isoform
GAC: glutaminase C
ROS: reactive oxygen species
shRNA: small hairpin ribonucleic acid
PYGB: glycogen phosphorylase, brain isoform
COPD: chronic obstructive pulmonary disease
3BP: 3-bromopyruvate
PET: positron emission tomography
mTOR: mammalian target of rapamycin
PTEN: phosphatase and tensin homolog
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HIF-1α: hypoxia-inducible factor-1αGLS: glutaminase
FH: fumarate hydratase
SQR: succinate dehydrogenase
HLRCC: hereditary leiomyomatosis and renal cell cancer
GIST: gastrointestinal stromal tumors
HBP: hexosamine biosynthetic pathway
OGT: O-GlcNAc transferase
PFK: phosphofructokinase
SIRM: stable isotope-resolved metabolomics
NLST: national lung cancer screening trial
LDCT: low-dose computed tomography
SCLC: small-cell lung cancer
ACS: American Cancer Society
RT: radiotherapy
SBRT: stereotactic body radiotherapy
MSA: methylseleninic acid
SeM: selenomethionine
SELECT: selenium and vitamin E cancer prevention trial
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